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Abstract
The EFSA Panel on Contaminants in the Food Chain (CONTAM) established a tolerable daily intake
(TDI) for T2 and HT2 of 0.02 lg/kg body weight (bw) per day based on a new in vivo subchronic
toxicity study in rats that conﬁrmed that immune- and haematotoxicity are the critical effects of T2
and using a reduction in total leucocyte count as the critical endpoint. An acute reference dose (ARfD)
of 0.3 lg for T2 or T2/kg bw was established based on acute emetic events in mink. Modiﬁed forms of
T2 and HT2 identiﬁed are phase I metabolites mainly formed through hydrolytic cleavage of one or
more of the three ester groups of T2. Less prominent hydroxylation reactions occur predominantly at
the side chain. Phase II metabolism involves conjugation with glucose, modiﬁed glucose, sulfate,
feruloyl and acetyl groups. The few data on occurrence of modiﬁed forms indicate that grain products
are their main source. The CONTAM Panel found it appropriate to establish a group TDI and a group
ARfD for T2 and HT2 and its modiﬁed forms. Potency factors relative to T2 for the modiﬁed forms
were used to account for differences in acute and chronic toxic potencies. It was assumed that
conjugates (phase II metabolites of T2, HT2 and their phase I metabolites), which are not toxic per
se, would be cleaved releasing their aglycones. These metabolites were assigned the relative potency
factors (RPFs) of their respective aglycones. The RPFs assigned to the modiﬁed forms were all either 1
or less than 1. The uncertainties associated with the present assessment are considered as high. Using
the established group, ARfD and TDI would overestimate any risk of modiﬁed T2 and HT2.
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Summary
Following a request from the European Commission, the EFSA Panel on Contaminants in the Food
Chain (CONTAM) assessed whether it is appropriate and feasible to set a group health based guidance
value (group HBGV) for T-2 toxin (T2) and HT-2 toxin (HT2) and their modiﬁed forms related to their
presence in food and feed, and to consider, whether it would be appropriate to use the parent
compound as a marker for toxicity. Modiﬁed forms of mycotoxins comprise all metabolites of the
parent molecule, which are formed in the fungus, infested plant and animals used for food and feed. It
is increasingly realised that not only mycotoxins itself, but also their modiﬁed forms may contribute to
the overall toxicity. Modiﬁed forms include phase I metabolites formed through oxidation, reduction or
hydrolysis of the parent toxin, as well as phase II metabolites arising from conjugation with
endogenous molecules. In the plant, these are particularly conjugates with glucose or sulfate and in
animals’ glucuronic acid.
Previous risk assessments from EFSA on T2/HT2 and on modiﬁed mycotoxins have been used as a
starting point for the present assessment. In addition, a systematic literature search has been carried
out to obtain up-to-date and comprehensive information on T2/HT2 and its modiﬁed forms. In this
opinion, the general principles for risk assessment were followed.
Before assessing whether modiﬁed forms of T2/HT2 could be included in a group HBGV for
T2/HT2, the CONTAM Panel decided to review new relevant data on T2/HT2 published after the
European Food Safety Authority (EFSA) assessment in 2011 to evaluate whether the established
tolerable daily intake (TDI) for T2/HT2 needed to be revised and if in addition there was a need also
to set an acute reference dose (ARfD) for T2/HT2.
T2 and HT2 are members of the type A group trichothecenes, which are tetracyclic sesquiterpenoids
produced by many species of Fusarium infesting crop plants. A large number of modiﬁed forms (phase
I and phase II metabolites) of T2/HT2 generated by fungi, plants and mammals have been identiﬁed
and characterised. These may occur together with T2 and HT2 as residues in food of plant and animal
origin. The predominant metabolic pathways are the hydrolytic cleavage of one or more of the three
ester groups of T2 yielding to neosolaniol (NEO), T2-triol and eventually T2-tetraol. Hydroxylation
reactions at various positions of T2 and of hydrolytic metabolites (predominantly at C-19, but also at
C-20 and C-8) appear to be less pronounced. Another phase I reaction, mostly performed by intestinal
and ruminal microﬂora, is de-epoxidation resulting in loss of toxicity. Phase II metabolism involves
conjugation of the parent compounds and their phase I metabolites with glucose, modiﬁed glucose,
and sulfate, feruloyl and acetyl groups.
There are appropriate analytical methods for T2, HT2 and their phase II metabolites and these are
mainly based on liquid chromatography–tandem mass spectrometry (LC–MS/MS) and appear to be
adequate in terms of analytical performance. Methods such as gas chromatography–mass
spectrometry (GC–MS) or liquid chromatography-ﬂuorescence detection (LC-FLD) are still in use in
control laboratories. Both approaches require excessive sample puriﬁcation and a derivatisation step
prior to the analysis, thus affecting the overall recovery and sensitivity. The analytical methods
available for phase I metabolites of T2 and HT2 need improvement regarding their sensitivity. There is
a lack of commercially available standards and reference materials.
There are few data on occurrence of modiﬁed forms of T2 and HT2 in plant-derived food products,
but grain products appear to be the main source of modiﬁed forms of T2 and HT2. The proportion of
their occurrence relative to the respective parent compounds, in the few samples where this has been
determined, varies widely.
There is a lack of occurrence data on modiﬁed forms of T2 and HT2 in food of animal origin.
Upon ingestion, T2 appears to be rapidly absorbed. It is rapidly hydrolysed to HT2 and distributed
to the liver, kidney and other organs without accumulation. No studies on absorption or distribution
of modiﬁed forms of T2 or HT2 have been identiﬁed. There are no data on absorption of phase I
metabolites from food. They are assumed to be easily absorbed, distributed and entering metabolism
as described for T2. Neither are there data available on the absorption of phase II metabolites of T2
and HT2. It is assumed that such phase II metabolites are hydrolysed in the gastrointestinal tract
after ingestion, releasing their aglycones, which can then be absorbed. This assumption is based on
the fact that conjugates of other trichothecenes may undergo intestinal hydrolysis followed by
absorption. It is expected that phase I metabolites will subsequently be subject to phase II
metabolism with conjugation to glucuronic acid or sulfate. Mammals excrete the phase I and phase II
metabolites of T2/HT2, and presumably also ingested modiﬁed forms within 2–3 days in urine and
faeces.
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Since the previous opinion in 2011, new in vivo acute toxicity studies (supported by subacute
studies) show that T2 and HT2 have anorectic effects upon short-term exposure. Emetic events
observed in mink upon single oral and intraperitoneal exposure to both T2 and HT2 were identiﬁed as
critical effects for setting an acute HBGV in the present opinion. A benchmark dose (BMD) analysis was
performed using a combined data set on the incidence of emetic events in mink exposed to either T2
or HT2 in two independent experiments. This approach was justiﬁed considering that the two toxins
show similar acute toxicity, are equipotent with regard to emetic response and appear to work via the
same mode of action. In addition, T2 is rapidly metabolised to HT2 in the organism. Using a
benchmark response (BMR) of 10% resulted in a benchmark dose 10% (BMD10) total conﬁdence
interval (BMDL10–BMDU10) of 2.97–49.8 lg T2 or HT2/kg body weight (bw) per day across the applied
models. Using an uncertainty factor (UF) of 10, the CONTAM Panel established a group ARfD of 0.3
(rounded from 0.297) lg T2 or HT2/kg bw. The phase I metabolite NEO showed equal emetic potency
and was therefore included in a group ARfD with T2 and HT2 with the same, molarity-based relative
potency factor (RPF) of 1. In the absence of toxicity data on phase II metabolites of T2, HT2 and
NEO, the CONTAM Panel assumed that these conjugates can be hydrolysed in the intestine and
therefore included them in the group ARfD and used the same RPFs of 1 as for their parent/modiﬁed
phase I metabolites.
In its previous opinion of 2011, the Panel concluded that T2 inhibits protein, DNA and ribonucleic
acid (RNA) synthesis, causes apoptosis, necrosis and lipid peroxidation and induces haemato- and
myelotoxicity. Reduction in antibody response to a speciﬁc antigen in a subacute 21-day pig study
was identiﬁed as the critical effect for human risk assessment. This effect was accompanied by other
haematotoxic effects including a reduced number of leucocytes. Since then, a new in vivo subchronic
toxicity study with rats (duration 90 days) has become available overall conﬁrming that immune- and
haematotoxicity are the critical effects of T2 upon repeated exposure. In this study, a dose-
dependent reduction in total leucocyte count, mainly caused by a reduced number of lymphocytes,
was observed. The CONTAM Panel identiﬁed this as the critical effect for setting a chronic health
based guidance value in the present opinion. Using a BMR of 10% on the basis of biological
considerations, the Panel calculated a BMDL10-BMDU10 conﬁdence interval of 3.33–27.6 lg T2/kg bw
per day across the applied models. The CONTAM Panel used the BMDL10 and an UF of 200, taking
into account 10 for interspecies and 10 for intraspecies variation and a factor of 2 because it was a
subchronic study and the toxic effect progressed during the whole study period reaching no plateau
at the end of the study. A TDI of 0.02 (rounded from 0.017) lg T2 or HT2/kg bw per day was
established.
Haematotoxicity, in particular with reduced production of leucocytes but also erythrocytes and
platelets, is the critical effect of T2. The underlying mode of action is protein synthesis inhibition,
induction of ribotoxic stress and apoptosis. Since T2 is rapidly metabolised to HT2 the toxicity of T2
might partly be attributed to HT2. No in vivo studies on haematotoxicity of modiﬁed forms of T2
and HT2 have been identiﬁed. However, it can be assumed that phase I metabolites of T2 and HT2
work via a similar mode of action, because some have been shown to cause protein synthesis
inhibition. The CONTAM Panel therefore considered it appropriate to include the modiﬁed forms NEO,
T2-triol and T2-tetraol in a group TDI with T2 and HT2 assuming dose addition as a model of joint
action. Because phase I metabolites show different potencies in inhibition of protein synthesis and
other toxic effects, it was decided to assign molarity-based RPFs for their inclusion in any risk
assessment. These RPFs were rounded up to half orders of magnitude to avoid spurious accuracy
and are 1 for T2 and HT2 and 19-HO-T2, and, based on signiﬁcantly lower toxic potency, 0.3 for
NEO and 19-HO-HT2 and 0.1 for T2-triol and T2-tetraol. Since phase II metabolites of T2, HT2,
NEO, T2-triol and T2-tetraol can be hydrolysed to their aglycones after ingestion, they were included
in the Group TDI. Thus, T2-3-Glc, T2-3-diGlc, T2-3-Sulf, T2-3-GlcA, 3-Ac-T2, 3-Fer-T2, HT2-3-Glc,
HT2-diGlc, HT2-GlcA and HT2-MalGlc were included in the group TDI by applying an RPF of 1.
NEO-Glc was included using a factor 0.3 and T2-triol-Glc and T2-tetraol-Glc by applying a factor of
0.1. The CONTAM Panel noted that none of the modiﬁed form of T2 and HT2 had a higher toxic
potency than T2 or HT2.
The overall uncertainty associated with including modiﬁed forms of T2 and HT2 into a group ARfD
and a group TDI in the present assessment is considered as high and its application would rather
overestimate than underestimate the risk. Uncertainty could be reduced, provided more data are made
available, particularly on the in vivo haematotoxicity of modiﬁed forms of T2 and HT2. For the group,
ARfD data on the ability of several modiﬁed forms to induce an emetic response are needed. Also
more data on the absorption and bioavailability of the major phase II metabolites present in plant
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products used for food and feed are needed. Further chemical characterisation of not fully
characterised modiﬁed forms should be performed. Certiﬁed reference materials and standards for the
modiﬁed forms of T2 and HT2 should be made available and more data on the occurrence of modiﬁed
forms of T2 and HT2 in food are needed in order to characterise risks using the group ARfD and group
TDI and the RPFs established in this opinion.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Following a request from the European Commission, the risks to human and animal health related
to modiﬁed forms of the Fusarium toxins zearalenone, nivalenol, T-2 and HT-2 toxins, and fumonisins
were evaluated in the scientiﬁc opinion on the risks for human health related to the presence of
modiﬁed forms of certain mycotoxins in food and feed,1 adopted by the EFSA Panel on Contaminants
in the Food Chain (CONTAM) on 25 November 2014.
The CONTAM Panel considered it appropriate to assess human exposure to modiﬁed forms of the
various toxins in addition to the parent compounds, because many modiﬁed forms are hydrolysed into
the parent compounds or released from the matrix during digestion. In the absence of speciﬁc toxicity
data, toxicity equal to the parent compounds was assumed for modiﬁed mycotoxins. Risk
characterisation was done by comparing exposure scenarios with reference doses of the parent
compounds.
The regulatory follow-up to this scientiﬁc opinion was discussed at the Expert Committee
‘Agricultural contaminants’ on 15 January 2015. The Standing Committee on Plants, Animals, Food and
Feed has been informed thereof at its meeting on 11 February 2015.2
Before taking regulatory measures as regards the modiﬁed mycotoxins, it was agreed that it is
appropriate to request the European Food Safety Authority (EFSA) to assess whether it is appropriate
and feasible to set a group health based guidance value (HBGV) for the parent compound and its
modiﬁed forms and to consider, if relevant, the appropriateness to use the parent compound as a
marker for the presence and toxicity of the parent compound and its modiﬁed forms.
1.2. Terms of Reference as provided by the requestor
In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/2002, the Commission asks EFSA for
scientiﬁc opinions to assess whether it is appropriate and feasible to set a group HBGV for the parent
compound and its modiﬁed forms for zearalenone, fumonisins, nivalenol, and T-2 and HT-2 toxin and
to consider, if relevant, the appropriateness to use the parent compound as a marker for the presence
and toxicity of the parent compound and its modiﬁed forms for these mycotoxins.
The four requested scientiﬁc opinions are:
1) assessment whether it is appropriate and feasible to set a group HBGV for zearalenone and
its modiﬁed forms identiﬁed in the CONTAM opinion on the risks for human health related to
the presence of modiﬁed forms of certain mycotoxins in food and feed, and to consider, if
relevant, the appropriateness to use the parent compound as a marker for presence and
toxicity of zearalenone and its modiﬁed forms.
2) assessment whether it is appropriate and feasible to set a group HBGV for fumonisin B1 and
B2 and their modiﬁed forms identiﬁed in the CONTAM opinion on the risks for human health
related to the presence of modiﬁed forms of certain mycotoxins in food and feed and to
consider, if relevant, the appropriateness to use the parent compounds as a marker for the
presence and toxicity of fumonisin B1 and B2 and their modiﬁed forms.
3) assessment whether it is appropriate and feasible to set a group HBGV for nivalenol and its
modiﬁed forms identiﬁed in the CONTAM opinion on the risks for human health related to
the presence of modiﬁed forms of certain mycotoxins in food and feed and to consider, if
relevant, the appropriateness to use the parent compound as a marker for the presence and
toxicity of nivalenol and its modiﬁed forms.
4) assessment whether it is appropriate and feasible to set a group HBGV for T-2 and HT-2
toxin and their modiﬁed forms identiﬁed in the CONTAM opinion on the risks for human
health related to the presence of modiﬁed forms of certain mycotoxins in food and feed and
to consider, if relevant, the appropriateness to use the parent compound as a marker for the
presence and toxicity of T-2 and HT-2 toxin and their modiﬁed forms.
1 EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), 2014. Scientiﬁc Opinion on the risks for human and
animal health related to the presence of modiﬁed forms of certain mycotoxins in food and feed. EFSA Journal 2014;12
(12):3916, 107 pp. doi:10.2903/j.efsa.2014.3916 Available online: www.efsa.europa.eu/efsajournal
2 Summary report of the Standing Committee on Plants, Animals, Food and Feed, held in Brussels on 11 February 2015
(Section Toxicological Safety of the Food Chain), agenda item A.06. Report available at: http://ec.europa.eu/food/committees/
regulatory/scfcah/toxic/docs/sum_20150211_en.pdf
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1.3. Introduction to modiﬁed mycotoxins
Mycotoxins are secondary metabolites of ﬁlamentous fungi. They are usually low molecular weight
compounds and serve no function in the intermediary metabolism of the fungus, but provide
advantages with respect to its competition for nutrients and habitat. Consequently, many mycotoxins
are toxic for bacteria and other microorganisms. As mycotoxins are also toxic for humans and animals,
their presence in food and feed may pose a health risk.
Numerous mycotoxins have been characterised. Even though some of these may be metabolites of
the other, they are recognised as separate mycotoxins, e.g. HT-2 toxin (HT2) is a metabolite of T-2
toxin (T2). However, it is increasingly realised that also modiﬁed forms of these mycotoxins occur in
food and feed and that these modiﬁed forms should be taken into account for risk assessment,
because they may contribute to the toxicity of the parent toxin.
According to a recent deﬁnition, modiﬁed forms of mycotoxins comprise all biologically, chemically
and physically modiﬁed derivatives of the parent molecule, which are formed in the fungus, infested
plant and mammalian organism (Rychlik et al., 2014). This includes inter alia phase I metabolites
formed through oxidation, reduction or hydrolysis of the parent toxin, as well as phase II metabolites
arising from conjugation with endogenous molecules. Phase II metabolites formed in the plant through
conjugation with polar low molecular weight molecules, such as glucose or sulfate, have also been
called ‘masked’ mycotoxins because they were hard to capture by routine analysis (Rychlik et al.,
2014). However, after intake with the food or feed such conjugates may be hydrolysed in the digestive
tract, thereby releasing the parent toxin which may add to the total uptake of toxin. Therefore, phase
II metabolism in the plant or fungi is of paramount importance for the risk assessment of mycotoxins.
In the context of risk assessment of mycotoxins in food and feed, modiﬁed mycotoxins comprise all
metabolites of a given mycotoxin that occur in food or feed. These include phase I and II metabolites
formed in the fungus, infested plant used for food and feed or food (and feed) products of animal
origin. It does not include metabolites formed in humans, even if these may be similar.
1.4. Legislation
Article 2 of Council Regulation (EEC) No 315/933 stipulates that food containing a contaminant in
amount unacceptable for public health shall not be placed on the market, that contaminant levels
should be kept as low as can reasonably be achieved and that, if necessary, the European Commission
may establish maximum levels for speciﬁc contaminants. These maximum levels are laid down in the
Annex of Commission Regulation (EC) No 1881/20064 and may include maximum levels (MLs) for the
same contaminants in different foods, analytical detection limits and reference to the sampling and
analysis methods to be used. Neither for T2 and HT2 nor for their metabolites have MLs been set in
this regulation.
Commission Recommendation 2013/165/EU5 states that referring to the respective EFSA opinion
(EFSA CONTAM Panel, 2011) since the exposure estimates for T2 and HT2 are below the tolerable
daily intake (TDI) there is no immediate public health concern. However, in order to assess changes
and trends in exposure, it stipulates that the European Union (EU) Member States, with active
involvement of feed and food business operators, monitor the presence of T2 and HT2 in cereals and
cereal products and that any results should be provided on a regular basis to EFSA. It furthermore
provides indicative levels for the sum of T2 and HT2 in cereals and cereal products, from which
onwards/above investigations should be performed, certainly in the case of repetitive ﬁndings. These
indicative levels range from 15 lg/kg in cereal-based foods for infants to 2,000 lg/kg in oat milling
products (husks).
1.5. Interpretation of Terms of Reference
The CONTAM Panel took the assumption that the previous risk assessment of T2 and HT2 in food
and feed (EFSA CONTAM Panel, 2011) is comprehensively covering all relevant aspects of the
3 Council Regulation (EEC) No 315/93 of February 1993 laying down Community procedures for contaminants in food. OJ L 37,
13.2.1993, p. 1–5.
4 Regulation (EC) No 1881/2006 of the European Parliament and the Council of 19 December 2006 setting maximum levels for
certain contaminants in foodstuffs. OJ L 364, 20.12.2006, p. 5–24.
5 2013/165/EU: Commission Recommendation of 27 March 2013 on the presence of T-2 and HT-2 toxin in cereals and cereal
products Text with EEA relevance OJ L 91, 3.4.2013, p. 12–15.
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compound and therefore used it together with the recent opinion on modiﬁed fusarium toxins (EFSA
CONTAM Panel, 2014) as a starting point for the present assessment.
The CONTAM Panel decided to review the new relevant data on T2 and HT2 (i.e. published after
2010) to evaluate whether the TDI established for T2 and HT2 in 2011 needs to be revised and if in
addition there is a need also to set an acute reference dose for T2 and HT2.
The Panel then decided to present the modiﬁed forms of T2 and HT2 identiﬁed to date and
reviewed the appropriateness of the methods currently available for their analysis.
In line with the previous EFSA opinion on modiﬁed mycotoxins (EFSA CONTAM Panel, 2014),
modiﬁed T2 and HT2 occurring in plants (arising from both plant and fungal metabolism), formed as a
consequence of food processing and transfer from feed to livestock were considered for possible
inclusion in group HBGVs.
In order to assess whether it was appropriate to include the modiﬁed forms of T2 and HT2 in
group HBGVs with T2 and HT2, all data available and relevant for that task were evaluated.
2. Data and methodologies
2.1. Methodology for data collection and study appraisal
The CONTAM Panel considered the previous assessments on T2 and HT2 (EFSA CONTAM Panel,
2011) and on modiﬁed fusarium toxins including modiﬁed T2 and HT2 (EFSA CONTAM Panel, 2014) as
comprehensive, covering all relevant publications on T2 and HT2 and its modiﬁed forms, respectively,
until those dates. All publications referenced therein have been considered, wherever appropriate, also
for the present evaluation.
In order to cover also new publications not considered in these previous assessments, a systematic
and comprehensive search for literature was conducted for peer-reviewed original research pertaining
to T2 and HT2 and its modiﬁed forms published after 2010 including scientiﬁc literature dealing with
analytical determination, chemistry, occurrence, toxicokinetics and toxicity of T2 and HT2 and/or its
modiﬁed forms. Studies on analytical methods, chemistry and occurrence of the parent compounds T2
and HT2 only, however, were excluded since not considered of relevance for the present assessment.
Date, search strings, data bases used and numbers of publications retrieved and used for
assessment are presented in detail in Appendix A. In total, 1,087 citations/abstracts were obtained.
Those considered relevant by expert judgement were included in the present assessment. Only papers
in English language were considered for inclusion in the assessment.
Since the 2011 opinion on T2 and HT2 did not include information on metabolites, in order to
obtain information on the toxicity of T2 metabolites additional publications on T2-tetraol and
neosolaniol were collected using the same databases as above, search terms T2-tetraol AND tox* and
neosolaniol AND tox*, but applying no time limit. This search yielded a total of 335 publications of
which 56 were considered as potentially relevant for the present assessment.
During the development of the opinion, additional relevant publications not retrieved in the above-
mentioned literature evaluation have been identiﬁed and considered for the assessment when relevant.
2.2. Methodology applied for hazard assessment
The CONTAM Panel applied the general principles of the risk assessment process for chemicals in
food as described by the World Health Organization (WHO, 2009), which include hazard identiﬁcation
and characterisation, exposure assessment and risk characterisation. In addition to the principles
described by WHO (2009), EFSA guidance pertaining to risk assessment (EFSA Scientiﬁc Committee,
2009) and on default values (EFSA Scientiﬁc Committee, 2012) have been applied for the present
assessment.
3. Previous assessments
In the Scientiﬁc Opinion on the risks for animal and public health related to the presence of T2 and
HT2 in food and feed (EFSA CONTAM Panel, 2011), it was noted that the pig is among the most
sensitive species towards T2 and that immunological and haematological effects are the most
sensitive/critical endpoints. Using the data obtained on reduction in antibody response to a speciﬁc
antigen (for which a lowest-observed-adverse-effect level (LOAEL) of 29 lg T2/kg body weight (bw)
per day was observed while a no no-observed-adverse-effect level (NOAEL) could be identiﬁed) in a
benchmark dose (BMD) analysis a BMDL05 of 10 lg T2/kg bw per day was derived for T2. Since T2 is
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rapidly metabolised to HT2 and the toxicity of T2 might at least partly be attributed to HT2, a group
TDI of 0.1 lg/kg bw per day was established for the sum of T2 and HT2 by applying an uncertainty
factor (UF) of 100 to the BMDL05.
In the Scientiﬁc Opinion on the risks for human and animal health related to the presence of
modiﬁed forms of certain mycotoxins in food and feed (EFSA CONTAM Panel, 2014), no speciﬁc
information on the toxic effects of the modiﬁed forms of T2 and HT2 could be identiﬁed. However, the
chemistry and toxicokinetics of T2 and HT2 as well as general considerations of biotransformation
suggested that T2 and HT2 conjugates may be cleaved in the gastrointestinal tract releasing T2 and
HT2. Taking a pragmatic approach until more information became available, the CONTAM
Panel assumed that modiﬁed forms of T2 and HT2 have the same toxicological proﬁle and potency as
their parent compounds. Based on occurrence data available at that time (2014), it was then assumed
that modiﬁed forms of T2 and HT2 add another 10% to the exposure to T2 and HT2.
4. Chemistry
T-2 toxin and HT-2 toxin (Figure 1) are members of the trichothecene family, which represents the
largest group of Fusarium mycotoxins and comprises more than 150 compounds. The common
structure of all trichothecenes is a tetracyclic sesquiterpene with a spiro-epoxide group at C-12 and C-
13 and an oleﬁnic double bond between C-9 and C-10. According to the substituents of the tetracyclic
ring system, trichothecenes are grouped into different types (A–D). T-2 and HT-2 toxin belong to the
type A trichothecenes, which are characterised by an esteriﬁed or free hydroxyl group at C-8, or an
unsubstituted C-8. In contrast, all type B trichothecenes, e.g. nivalenol and deoxynivalenol (DON),
carry a keto group at C-8. Type A and B compounds constitute the majority of trichothecene
contaminants in food and feed.
The biosynthesis of T-2 and HT-2 toxin involves the initial cyclisation of farnesyl phosphate to the
bicyclic sesquiterpene trichodiene, which does not contain oxygen, followed by a complex sequence of
hydroxylation, epoxidation, further cyclisation, and acylation reactions (for review, see McCormick
et al., 2011). HT-2 toxin arises through hydrolysis of the 4-acetoxy group of T-2 toxin and is a
metabolite of T-2 toxin formed in fungi, plants and animals.
In this opinion, the nomenclature according to the International Union of Pure and Applied
Chemistry (IUPAC) rules was applied. It should be noted that the numbering of the isovaleroyl group
of T-2 and HT-2 toxin is not consistent in the literature. Instead of 17–19 (see Figure 1), some
publications use 10 to 30, respectively.
In general, plants, microorganisms and animals biotransform mycotoxins by phase I metabolism,
which includes oxidation, reduction and hydrolysis of the parent (fungal) compounds, and phase II
metabolism, which comprises all conjugation reactions. While phase II metabolites formed in the
mammalian organism are usually excreted via urine and/or bile, plants store conjugated metabolites in
vacuoles and/or attach them to structures of the cell wall. The latter processes are sometimes referred
to as phase III metabolism or compartmentation.
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Figure 1: Chemical structures of T-2 toxin (left) and HT-2 toxin (right)
Group HBGV for T2 and HT2 and their modiﬁed forms
www.efsa.europa.eu/efsajournal 11 EFSA Journal 2017;15(1):4655
4.1. Parent compounds and phase I metabolites
T-2 toxin, in the older literature also referred to as fusariotoxin T-2, insariotoxin, or mycotoxin T-2,
has the IUPAC name (2a,3a,4ß,8a)-4,15-bis(acetoxy)-3-hydroxy-12,13-epoxytrichothec-9-en-8-yl
3-methylbutanoate (Chemical Abstracts Service, CAS No 21259-20-1, C24H34O9, molecular weight (MW)
466). It is a colourless crystalline solid with a melting point (m.p.) of 151–152°C (Bamburg et al., 1968).
HT-2 toxin has the IUPAC name (2a,3a,4ß,8a)-15-acetoxy-3,4-dihydroxy-12,13-epoxytrichothec-9-
en-8-yl 3-methylbutanoate (CAS No 26934-87-2, C22H32O8, MW 424). It is a colourless crystalline solid
with a m.p. of 151–152°C (Bamburg et al., 1968).
The solubility of T-2 toxin and HT-2 toxin is low in water and petroleum ether, but good in ethanol,
ethyl acetate, chloroform, dimethylsulfoxide and other organic solvents.
Although the trivial names of T-2 toxin and HT-2 toxin are short, they are frequently abbreviated in
the scientiﬁc literature as T2 and HT2, respectively. These abbreviations are also used in this Opinion,
mainly because they are of advantage for abbreviating the more complex names of the phase II
metabolites of T2 and HT2 (see Section 4.2).
As discussed in more detail in Sections 6 and 7.3.1, numerous phase I metabolites of T2 and HT2
have been identiﬁed in fungal cultures and plants, as well as in studies with experimental animals.
They are listed in Table 1, and the chemical structures of the key metabolites arising from the major
metabolic pathways are depicted in Figure 2. As T2 and its metabolites lack a strong chromophore, the
analytical method of choice is often liquid chromatography–mass spectrometry (LC–MS) analysis, which
has the advantage of an efﬁcient separation from complex matrices and high sensitivity (see
Section 5). Therefore, the element formulas and molecular weights of the metabolites are given in
Table 1. It should be noted that some of the phase I metabolites are isomeric (e.g. the regioisomers of
the monohydroxylated metabolites and their de-epoxidation products), which has to be taken into
account in LC–MS analysis.
Table 1: T2 and HT2 and their phase I metabolites
Compound(a) Element formula Molecular weight
T2 C24H34O9 466
19-HO-T2(b) (TC-1) C24H34O10 482
iso-TC-1(c) C24H34O10 482
20-HO-T2(d) C24H34O10 482
DE-T2 C24H34O8 450
15-Deacetyl-T2 C22H32O8 424
DE-19-HO-T2(b) C24H34O9 466
15-Deacetyl-19-HO-T2 C22H32O9 440
HT2 C22H32O8 424
7-HO-HT2 C22H32O9 440
19-HO-HT2(b) (TC-3) C22H32O9 440
20-HO-HT2(d) C22H32O9 440
7,19-diHO-HT2(e) C22H32O10 456
DE-HT2 C22H32O7 408
DE-19-HO-HT2(b) C22H32O8 424
Neosolaniol (NEO) C19H26O8 382
4,8-Diacetyl-T2-tetraol (NT-1 toxin)(f) C19H26O8 382
15-Deacetyl-NEO (NT-2 toxin) C17H24O7 340
4-Deacetyl-NEO (TMR-1 toxin) C17H24O7 340
T2-triol C20H30O7 382
19-HO-T2-triol(b) C20H30O8 398
DE-T2-triol C20H30O6 366
DE-19-HO-T2-triol(b) C20H30O7 382
T2-tetraol C15H22O6 298
15-Acetyl-T2-tetraol C17H24O7 340
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The pathways of biotransformation of T2 and HT2 in fungi, plants and mammals are essentially the
same and are depicted in Figure 2. Essentially, the predominant metabolic pathway A is the hydrolytic
cleavage of one or more of the three ester groups of T2. Pathway B involves hydroxylation reactions at
various positions of T2 and of hydrolytic metabolites. Hydroxylation occurs predominantly at C-19, but
also at C-20, C-8 and others. Pathway C constitutes the reduction of the epoxide group at C-12 and
C-13 to an oleﬁnic double bond.
4.2. Phase II metabolites
In most phase II metabolic pathways, water-soluble conjugates are formed through covalent
binding of the parent compound or a phase I metabolite with a highly polar molecule, e.g. a
carbohydrate or sulfate from the metabolising organism. In most cases, activation of the conjugating
moiety and a transferase enzyme are needed to form the covalent bond. Sulfate is used as a
conjugate moiety by fungi, plants and animals. Different carbohydrates are also utilised by plants and
fungi, the major carbohydrate employed for conjugation is glucose, whereas animals use glucuronic
acid. The glucose can be further modiﬁed in plants, e.g. by esteriﬁcation with another hexose or with
malonic acid. Moreover, plants can use acetate and ferulate for conjugation. The major conjugating
moieties in plants are depicted in Figure 3.
Compound(a) Element formula Molecular weight
DE-15-Acetyl-T2-tetraol C17H24O6 324
The trivial designations used for some of the metabolites are also given. The structural formulas are depicted in Appendix B.
(a): HO: hydroxyl; DE: de-epoxy; NEO: neosolaniol.
(b): Also denoted as 30 in the literature due to different numbering system.
(c): Regioisomer of TC-1 with acetoxy group at C-3 and free hydroxy group at C-4.
(d): Also denoted as 40.
(e): Also denoted as 30,7.
(f): Regioisomer of NEO with acetoxy group at C-8 and free hydroxy group at C-15.
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For the abbreviation of the carbohydrates and their modiﬁed forms used in phase II metabolism,
the same nomenclature as in the Scientiﬁc Opinion on the risks for human and animal health related to
the presence of modiﬁed forms of certain mycotoxins in food and feed (EFSA CONTAM Panel, 2014)
and in the Scientiﬁc Opinion on the appropriateness to set a group-based guidance value for
zearalenone and its modiﬁed forms (EFSA CONTAM Panel, 2016) will be used. These abbreviations,
which are common in carbohydrate chemistry, clearly designate the speciﬁc carbohydrate (e.g. Glc for
glucose, Man for mannose, Xyl for xylose, etc.) and its oxidation state (e.g. GlcA for glucuronic acid).
For a complete designation, also the type of ring (p for pyranose or f for furanose), the conﬁguration
(D or L), and the type of glycosidic bond (a or b) could be given, if known. For further details, see
Scientiﬁc Opinion on the risks for human and animal health related to the presence of modiﬁed forms
of certain mycotoxins in food and feed (EFSA CONTAM Panel, 2014).
The phase II metabolites of T2, HT2 and their phase I metabolites identiﬁed in fungal and yeast
cultures, plants and mammals are summarised in Table 2. The microbial and plant metabolites are
discussed in more detail in Section 6. Conjugation of with glucuronic acid does not occur to an
appreciable extent in plants and fungi but is a major pathway of phase II metabolism in animals and
humans (Section 7.3.2).
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Table 2: Phase II metabolites of T2 and HT2 detected in fungi, yeast and plants
Metabolite(a) Element formula Molecular weight Comment
T2-3-a-Glc C30H44O14 628 Fully characterised (
1H and 13C NMR)
T2-3-b-Glc C30H44O14 628 Fully characterised (
1H and 13C NMR)
T2-3-diGlc C36H54O19 790 Exact chemical structure unknown
T2-3-GlcA C30H42O15 642 Fully characterised (
1H and 13C NMR)
T2-Sulf C24H34O12S 546 Fully characterised (
1H and 13C NMR)
3-Ac-T2 C26H36O10 508 Chemically synthesised, no NMR spectra
3-Fer-T2 C34H42O12 642 Exact chemical structure unknown
HT2-3-Glc C28H42O13 586 Exact chemical structure unknown
HT2-diGlc C34H52O18 748 Exact chemical structure unknown
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The vast majority of the metabolites listed in Table 2 have only been tentatively identiﬁed, usually
based on liquid chromatography–high resolution mass spectrometry (LC–HRMS), liquid chromatography–
tandem mass spectrometry (LC–MS/MS) and enzymatic cleavage to release the aglycones. Chemical
syntheses have been reported for T2-3-Glc, T2-Sulf and 3-Ac-T2, while T2-3-GlcA, HT2-3-GlcA and
HT2-4-GlcA have been prepared by enzymatic glucuronidation of the respective aglycones using pig liver
microsomes.
T2-3-Glc is a major conjugate of T2 and formed in fungi, yeast and plants (see Section 6).
Glycosides can exist in two stereoisomeric forms (a and b) which differ in the conﬁguration of the
glycosidic C-atom. The a-anomer of T2-3-Glc was obtained from incubations of T2 with three species
of the yeast Blastobotrys (McCormick et al., 2012), and the b-anomer of T2-3-Glc has been chemically
synthesised (McCormick et al., 2015). Both anomers have been fully characterised by 1H and 13C NMR
spectroscopy. When LC–MS/MS was used to compare both anomers to the T2-3-Glc isolated from
wheat and oats naturally infected with Fusarium fungi, the latter was found to be the a-anomer, based
on high-performance liquid chromatography (HPLC) retention time and tandem mass spectrometry
(MS/MS) (McCormick et al., 2015).
Fruhmann et al. (2014) have recently synthesised the ammonium salt of T2-3-Sulf and
characterised it by HRMS, 1H and 13C nuclear magnetic resonance (NMR), in order to obtain a
reference compound for this metabolite. To date, however, no report has yet appeared on the
detection of T2-3-Sulf in food or feed, which is to be expected in view of the reported formation of
sulfates of closely related trichothecenes such as DON (Warth et al., 2015).
3-Ac-T2 is accessible by simple acetylation of T2 (Nathanail et al., 2015), but its full spectroscopic
characterisation has not yet been reported.
Welsch and Humpf (2012) have isolated T2-3-GlcA, HT2-3-GlcA and HT2-4-GlcA from incubations of
T2 with pig liver microsomes and activated glucuronic acid. In addition to direct glucuronidation of T2,
which has only one hydroxyl group, the microsomes catalysed the deacetylation of T2 to HT2 and the
subsequent formation of two regioisomeric HT2 glucuronides, which could be separated by HPLC. All
three glucuronides were puriﬁed by preparative HPLC and characterised by NMR and MS.
5. Analytical methods
Methods for analysis of T2 and HT2 are well established and can be applied for the analysis of both
food and feed (in particular cereals) and biological samples (such as body ﬂuids).
The CONTAM Panel has extensively reviewed the analytical methods developed for T2 and HT2 in
the Scientiﬁc Opinion on the risks for animal and public health related to the presence of T-2 and HT-2
toxin in food and feed (EFSA CONTAM Panel, 2011), thus this opinion will consider only those methods
published since 2011.
T2 and HT2 are usually analysed together with some other Fusarium toxins such as DON or
zearalenone. As for other Fusarium mycotoxins, sample extraction is based on mixtures of acetonitrile/
water or methanol/water, acidiﬁed with acetic or formic acid (De Girolamo et al., 2013). Especially,
when compound feed is considered, sample clean-up is often performed to reduce matrix effects
(Chen et al., 2013; De Girolamo et al., 2013). Recently, the use of liquid–liquid partition or ‘Quick,
Metabolite(a) Element formula Molecular weight Comment
HT2-3-GlcA C28H40O14 600 Fully characterised (
1H and 13C NMR)
HT2-4-GlcA C28H40O14 600 Fully characterised (
1H and 13C NMR)
HT2-MalGlc C31H44O16 672 Exact chemical structure unknown
HO-HT2-Glc C28H42O14 602 Exact chemical structure unknown
HO-HT2-MalGlc C31H44O17 688 Exact chemical structure unknown
3-Ac-HT2 (iso-T2) C24H34O9 466 Regioisomer of T2, tentatively identiﬁed
T2-Triol-Glc C26H40O12 544 Exact chemical structure unknown
T2-Tetraol-Glc C21H32O11 460 Exact chemical structure unknown
15-Ac-T2-tetraol-Glc C23H34O12 502 Exact chemical structure unknown
NEO-Glc C25H36O13 544 Exact chemical structure unknown
The structural formulas of the fully characterised metabolites are presented in Appendix C.
(a): Abbreviations of conjugate moieties: Glc: glucose; diGlc: diglucose; GlcA: glucuronic acid; Sulf: sulfate; Ac: acetyl; Fer:
feruloyl; MalGlc: malonylglucose; NEO: neosolaniol; NMR: nuclear magnetic resonance.
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Easy, Cheap, Effective, Rugged and Safe’ (QuEChERS) clean-up has been reported when matrices
different from grains are considered (Arroyo-Manzanares et al., 2013; Azaiez et al., 2014).
Methods, such as gas chromatography–mass spectrometry (GC–MS) or liquid chromatography-
ﬂuorescence detection (LC-FLD), are still in use in control laboratories. Both approaches require
excessive sample puriﬁcation and a derivatisation step prior to the analysis, thus affecting the overall
recovery and sensitivity (Burek et al., 2011; Amelin et al., 2013a,b).
Similarly to other Fusarium toxins, the method used for the analysis of T2, HT2 and some of their
modiﬁed forms (NEO, T2 and HT2 glucosides) has been LC–MS/MS, often as a multitoxin approach.
However, no validated quantiﬁcation methods for modiﬁed forms have been reported so far. Apart
from NEO, modiﬁed forms are mainly detected with screening or semiquantitative methods, without
properly optimised analytical parameters. Such methods might be inadequate with regard to recovery
and sensitivity.
The two studies in which conjugated forms were determined were based on acetonitrile/water or
methanol/water extraction followed by LC–MS/MS quantiﬁcation, using a multitoxin approach (Busman
et al., 2011; De Boevre et al., 2012). In both studies, conjugated forms were included as target
analytes based on theoretical MS transitions, due to the lack of commercial standards. Similarly, the
quantiﬁcation of T2-Glc and HT2-Glc was based on extrapolation of chromatographic peak areas from
T2 and HT2. This could strongly affect data reliability and accuracy. Only in one study so far, both
anomeric forms of T2-Glc were synthesised and used as reference compound for LC–MS/MS analysis
(McCormick et al., 2015).
A more recent approach is based on ambient mass spectrometry, such as direct-analysis-in-real-
time mass spectrometry (DART-MS). This method, which requires the use of an isotope-labelled
internal standard for quantiﬁcation, allows for an extremely rapid analysis with very good sensitivity
(Busman and Maragos, 2015). However, the authors reported a sixfold lower sensitivity for HT2 than
for T2, the limit of quantiﬁcation being 300 lg/kg and 50 lg/kg, respectively.
Immunochemical methods have been proposed for the simultaneous determination of T2 and
T2-Glc. In a study by Maragos et al. (2013), a monoclonal antibody was speciﬁcally designed and
validated towards T2 and T2-Glc. Very low cross-reactivity towards HT2 was seen. When used in an
enzyme-linked immunosorbent assay, the antibody gave a median inhibition concentration in the low
ng/mL range.
When both anomeric forms of T2Glc were considered, the cross-reactivity of the antibody towards
the a- and b-forms was 100% and 57% (McCormick et al., 2015). However, the system was not yet
applied to real samples.
6. Occurrence
The occurrence of T2 and HT2 in food and feed has been previously considered by the CONTAM
Panel (EFSA CONTAM Panel, 2011). Modiﬁed forms of T2 and HT2 have been described in food from
plant origin, as a consequence of the biotransformation performed by plants and/or fungi. The
chemistry of T2 and HT2 and their phase I and II metabolites is described in detail in Section 4,
including the chemical structures of the major phase I metabolites including their interrelationships,
which are depicted in Figure 2 of Section 4. The formation of phase I and phase II metabolites in
mammals is described in Section 7.3. The chemical structures of all phase I and phase II metabolites
of T2 and HT2 are presented in Appendices B and C, respectively.
In Table 3, the origin of the major modiﬁed forms of T2 and HT2 that might occur in food or feed
and reported so far in the literature are listed.
Table 3: Occurrence of modiﬁed forms of T2 and HT2 in food (plants, fungi and mammals)
Modiﬁed form Formed in plants Formed in fungi Formed in mammals
NEO Torp and Langseth (1999) Wu et al. (2011)
T2-Triol* Torp and Langseth (1999) Wu et al. (2014)
T2-Tetraol* Torp and Langseth (1999) Wu et al. (2014)
T2-Glc** McCormick et al. (2012) Busman et al. (2011)
3-Ac-T2* Nathanail et al. (2015) McCormick et al. (2012)
Nathanail et al. (2016)
3-Fer-T2* Nathanail et al. (2015)
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Of particular importance for the health assessment of modiﬁed forms of mycotoxins in food and
feed is the question where the phase I and II metabolites are formed, i.e. in the fungi, plants or
animals and enter the food chain. In contrast to animals, which tend to eliminate water-soluble
metabolites through urine and faeces, phase I and phase II metabolites formed in the fungus and/or
plant must be expected to remain in the infested plant and may therefore reach the consumer via food
items containing the contaminated plant material.
Modiﬁed forms of T2 and HT2 obtained by phase I metabolism have been less frequently reported
in the literature, with the only exception of NEO that has been described as fungal metabolite in many
commodities. This is likely due to the fact that NEO is the only phase I metabolite of T2 and HT2
commercially available as standard.
The formation of phase I metabolites T2-triol and T2-tetraol have been reported in fungal culture
(Torp and Langseth, 1999). Several yeast strains have been reported to be able to biotransform T2 and
HT2 to their phase I metabolites. McCormick et al. (2012) investigated several Trichomonascus clade
(n = 23) and Blastobotrys (n = 19) yeast strains. The formation of 3-Ac-T2, NEO and T2-Glc were
reported. Some species performed more than one type of biotransformation reaction. Very recently,
Nathanail et al. (2016) identiﬁed 3-Ac-T2 and HT2-Sulf as products by Saccharomyces pastorianus in
brewer’s wort.
Phase II conjugates of T2 and HT2 are mainly formed in plants. However, T2-Glc and HT2-Glc
glucosides may also result from fungal metabolism. Busman et al. (2011) were the ﬁrst to detect and
tentatively identify the 3-O-Glc of T2 and HT2 in cultures of Fusarium sporotrichioides as well as in
wheat and oats. The formation of HT2-Glc glucoside and NEO-Glc in Fusarium langsethiae isolates
cultured on durum wheat was reported by Lattanzio et al. (2013).
McCormick et al. (2015) demonstrated that T2-Glc produced by fungi and by plant can be
anomerically different as fungal biotransformations have been shown to preferentially result in the
a-Glc, while plant enzymatic pathways yield the b-Glc (McCormick et al., 2015).
Besides conjugation with glucose, T2 and HT2 can be further biotransformed in plants following
other phase II pathways resulting in other conjugates. In particular, Nathanail et al. (2015) and Meng-
Reiterer et al. (2015) studied the metabolism of T2 and HT2 in wheat and barley, respectively, by
applying uniformly 13C-labelled toxins to the ﬂowering ears of wheat plants and proﬁling the
metabolites using untargeted screening and quantitative LC–HRMS analysis. A total of 12 T2-derived
and 11 HT2-derived biotransformation products were detected. Previously reported mono- and diGlcs
were conﬁrmed, and several malonylglucosylated, acetylated and feruloylated metabolites were
reported for the ﬁrst time. In addition, the time courses of metabolite formation were determined.
Phase II metabolism proceeded rapidly and was almost completed within 1 week after a single
exposure in ﬂowering wheat ears.
Modiﬁed form Formed in plants Formed in fungi Formed in mammals
HT2-3-Glc Nathanail et al. (2015) Busman et al. (2011)
HT2-diGlc Veprikova et al. (2012)
HT2-Sulf Nathanail et al. (2016)
T2-diGlc Veprikova et al. (2012)
HT2-MalGlc* Nathanail et al. (2015)
HO-HT2-Glc* Nathanail et al. (2015)
HO-HT2-MalGlc* Nathanail et al. (2015)
3-Ac-HT2* Nathanail et al. (2015)
T2-Triol-Glc* Nathanail et al. (2015)
T2-Tetraol-Glc* Nathanail et al. (2015)
15-Ac-T2-tetraol-Glc* Nathanail et al. (2015)
NEO-Glc Nakagawa et al. (2013a) Lattanzio et al. (2013)
Glc: glucose; Ac: acetyl; Fer: feruloyl; diGlc: diglucose; Sulf: sulfate; MalGlc: malonylglucose; NEO: neosolaniol.
*: The compound has been found in model plants (i.e. wheat, barley) after artiﬁcial fungal inoculation, but there is no data
about occurrence in the ﬁeld.
**: Elucidated as T2-3-a-Glc in plants and T2-3-b-Glc in microorganisms (McCormick et al., 2015).
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6.1. Occurrence of modiﬁed forms of T2 and HT2 in food of plant origin
6.1.1. Phase I metabolites
Although plants and fungi may produce phase I metabolites of T2 and HT2, the CONTAM
Panel could only identify very few relevant data for their occurrence in food. Among phase I
metabolites, only NEO and T2-tetraol were reported in food commodities. Recently, Garcıa-Moraleja
et al. (2015) reported the occurrence of NEO in brewed coffee samples (n = 169). According to the
authors, NEO was found in 13% of the samples in the concentration range of 29–314 lg/kg (mean:
86.7 lg/kg). The same authors reported the occurrence of T2 and HT2 in 29% and 9% of the samples
(mean concentration: 2.4 and 12.2 lg/kg), respectively. Pereira et al. (2015) reported the occurrence
of NEO (87 lg/kg) and T2-tetrol (112 lg/kg) in one out of nine baby food samples containing cereals,
using GC–MS as an analytical method. NEO was also found at trace level in barley ﬁeld malt samples
from northern Italy (Lattanzio et al., 2015).
6.1.2. Phase II metabolites
Many conjugated forms of T2 and HT2 have been reported in the literature so far as a result of
plant metabolism. However, the few studies addressing the occurrence of such forms in grains and
food products thereof analysed only occurrence of T2-3-Glc and HT2-3-Glc.
Lattanzio et al. (2012) estimated the occurrence of T2-3-Glc and HT2-3-Glc in artiﬁcially inoculated
wheat and oats. Collected data reported amounts of HT2-3-Glc and T2-3-Glc of up to 27% and 24%
of their parent compounds, respectively (mean: 10%). The same authors found up to 37% HT2-3-Glc
compared to parent compound, depending on the harvest season (Lattanzio et al., 2013). In a more
recent survey, the occurrence of T2 and HT2 glucosides was reported in ﬁeld barley (Lattanzio et al.,
2015). In this study, HT2-3-Glc was detected at levels of up to 163 lg/kg in 17 out of 18 barley
samples, whereas T2-3-Glc was detected in only a few samples and at low lg/kg levels. The sum of
T2 and HT2 conjugates ranged from 2% to 280% in comparison with the total of the parent forms.
Veprikova et al. (2012) detected monoglycosylated forms of T2 and HT2 in naturally contaminated
barley, wheat and oats, and also documented for the ﬁrst time the existence of one diglucoside of T2
and two diglucosides of HT2 in barley. Diglucosidic conjugates of T2 were reported in corn by
Nakagawa et al. (2013b). The same authors reported the detection of a conjugate of the phase I
metabolite NEO in corn (Nakagawa et al., 2013a).
In a survey, De Boevre et al. (2012) collected 30 samples from a variety of food and feed matrices
including maize (n = 6), wheat (n = 6), oats (n = 6), cornﬂakes (n = 6) and bread (n = 6) from the
Belgian market. In 67% of the samples, T2 and HT2 were detected at a trace level. One oat sample
was contaminated with 118 lg/kg HT2 and 34 lg/kg T2, while the mean values in oats were 31 and
15 lg/kg, respectively. Although T2-3-Glc and HT2-3-Glc were included among the monitored
compounds, they were not detected in any sample in this survey, most probably because of the low
sensitivity of the methods applied.
A review on the occurrence of Fusarium mycotoxins in unprocessed cereals has been published by
Broekaert et al. (2015). The concentrations of conjugated T2 and HT2 were substantially lower than
those of T2 and HT2 in the samples where both T2 and HT2 and conjugated T2 and HT2 were
detected. The total number of samples containing conjugated T2 and HT2 was higher than samples
containing unconjugated T2 and HT2. For T2-3-Glc and HT2-3-Glc, the numbers of positive samples
were 73% and 80%, respectively (n = 15), with a mean and maximum concentration of 2.4 lg/kg and
11 lg/kg T2-3-Glc, and of 5.1 lg/kg and 15 lg/kg HT2-3-Glc. For T2 and HT2, the fractions of positive
samples were 45% and 54%, respectively (n = 321), with a mean and maximum concentration of
16.7 lg/kg and 377 lg/kg T2, and of 61 lg/kg and 834 lg/kg HT2. Overall, the mean concentrations
of conjugated T2 and HT2 were substantially lower than those of T2 and HT2, with an average
percentage of 8.3% for HT2-Glc and 14.4% for T2-Glc with respect to the parent compounds.
Nathanail et al. (2015) studied the occurrence of major Fusarium toxins and their modiﬁed forms in
oats (n = 31), barley (n = 34), and wheat (n = 30) from Finland. The method was calibrated for T2,
HT2 and HT2-3-Glc because of the available standard compounds. T2, HT2 and HT2-3-Glc were found
in 21%, 35% and 53% of the barley samples, and the mean values were 10.7, 20 and 10.8 lg/kg,
respectively. As far as oats are concerned, T2, HT2 and HT2-3-Glc were found in 61.3%, 74.2% and
58.1% of the samples, and the mean values were 60.1, 159 and 41.4 lg/kg, respectively. Finally, in
wheat, T2, HT2 and HT2-3-Glc were found in 46.7%, 63.3%, and 43.3% of the samples, and the
Group HBGV for T2 and HT2 and their modiﬁed forms
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2017;15(1):4655
mean values were 4.2, 9 and 15 lg/kg, respectively. Maximum concentrations were particularly high in
oats, reaching maximum values of 548, 1,830 and 300 lg/kg for T2, HT2 and HT2-3-Glc, respectively.
In contrast to the preliminary data on the occurrence of T2 and HT2 conjugates in grains indicating
an incidence of up to 10% of the parent compounds as presented in the previous opinion (EFSA
CONTAM Panel, 2014), the studies presented above reported higher occurrence rates of conjugates in
comparison with the parent compounds. This can be ascribed to improvements of analytical methods,
as well as to the variability in sampling time and harvest season conditions (i.e. grain varieties, climate).
Overall, the proportion of occurrence of modiﬁed forms of T2 and HT2 relative to the respective
parent compounds, in the few samples where this has been determined, varies widely.
6.2. Occurrence of modiﬁed forms of T2, HT2 and their modiﬁed forms
in food of animal origin
No relevant information about the occurrence of T2, HT2 or their modiﬁed forms in food of animal
origin has been identiﬁed by the CONTAM Panel. It can generally be assumed that at least a part of
them will be excreted (after conjugation in the case of phase I metabolites) by the animal prior to
slaughter and processing to food items. This assumption is supported by studies indicating that
animals rapidly excrete T2 and its metabolites in urine and faeces, mainly as glucuronides (EFSA
CONTAM Panel, 2011; Welsch and Humpf, 2012).
7. Toxicokinetics of T2 and HT2 and their modiﬁed forms
No studies on the toxicokinetics of modiﬁed forms (phase I metabolites and phase II metabolites)
of T2 or HT2 have been identiﬁed. The toxicokinetics of T2 and HT2 have been reviewed by the Joint
FAO/WHO Expert Committee on Food Additives (FAO/WHO, 2001) and EFSA (EFSA CONTAM Panel,
2011). The following sections will brieﬂy summarise the major ﬁndings and discuss in more detail
pertinent studies published since 2011. There are also some recent review papers on trichothecenes
including T2 and HT2 (Wu et al., 2014; Broekaert et al., 2015).
7.1. Absorption
Studies on the in vivo absorption of T2 and HT2 in animals after oral administration are very scarce.
To date, the bioavailability of T2 and HT2 has not been quantiﬁed. However, when tritium-labelled T2
was intraduodenually administered to bile duct-cannulated male rats, 45% and 57% of the dosed
radioactivity was excreted in the bile within 4 and 8 h, respectively (Coddington et al., 1989). Likewise,
about 40% of the total radioactive dose appeared in the efﬂuent blood within 50 min after injection of
tritium-labelled T2 into isolated autoperfused jejunal segments of rats (Conrady-Lorck et al., 1988).
Only minute amounts of T2 were observed in the bile and blood in these studies, suggesting an
extensive hydrolysis to HT2 and other metabolites during the rapid intestinal absorption of T2. The
presumed rapid absorption is consistent with the fact that the excretion of total radioactivity in the urine
and faeces of rats was completed 48 h after a single oral dose of tritium-labelled T2 administered by
gavage (Pfeiffer et al., 1988).
No studies on the absorption of modiﬁed forms (phase I and phase II metabolites) of T2 or HT2
have been identiﬁed.
7.2. Distribution
In rats and mice orally dosed with tritium-labelled T2, radioactivity was rapidly distributed to the
liver, kidney and other organs without accumulation in any organ (Matsumoto et al., 1978; EFSA
CONTAM Panel, 2011). Radioactivity was also detected in the fetuses of late pregnancy rats following
oral administration of tritium-labelled T2 (Lafarge-Frayssinet et al., 1990). Wang et al. (2014) have
recently studied the transfer mechanisms of T2 and HT2 in human placental choriocarcinoma (BeWo)
cells, which are derived from human choriocarcinoma cells and considered as an in vitro model for
maternal–fetal exchange. Using LC–MS/MS analysis, an active transport mechanism was suggested for
the uptake of T2 into BeWo cells, whereas passive diffusion was observed for HT2.
No studies on the distribution of modiﬁed forms (phase I and phase II metabolites) of T2 or HT2
have been identiﬁed.
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7.3. Metabolism
The complex metabolism of T2 and HT2 in animals and humans has been addressed in the
previous risk assessment of T2 and HT2 in food and feed (EFSA CONTAM Panel, 2011) and are also
discussed in a recent review (Wu et al., 2014). No information on the biotransformation of modiﬁed
forms of T2/HT2 from food has been identiﬁed.
7.3.1. Phase I metabolism
Most of the numerous phase I metabolites of T2 and HT2 known to date have been reported prior
to 2011, and only few minor metabolites have been identiﬁed since then. As depicted in Figure 2
(Section 4.1), the phase I metabolites arise from three different biotransformation reactions, i.e.
(A) hydrolysis of one or more of the ester groups, (B) hydroxylation at various positions and (C)
de-epoxidation. These metabolic reactions may also occur in combination, and the resulting phase I
metabolites are listed in Table 1 (see Section 4.1).
Various enzymes are involved in the phase I metabolism of T2 and HT2 in mammals (Wu et al.,
2014). While the hydrolytic pathway A is mediated by carboxylesterases located in hepatic microsomes
and white and red blood cells, a variety of cytochrome P450 (CYP) isoforms has been implicated in the
hydroxylation reactions of pathway B. The enzymes accounting for the de-epoxidation pathway C have
yet to be clariﬁed.
A few minor metabolites (not included in Table 1) were tentatively identiﬁed more recently in
Wistar rats in vitro and in vivo (Yang et al., 2013). These are 15-deacetyl-T2, 15-deacetyl-19-hydroxy-
T2, 7,19-dihydroxy-T2 and a regioisomer, 7-hydroxy-HT2 and a regioisomer, as well as another
regioisomer of hydroxy-T2 and dihydroxy-T2 not further identiﬁed.
No in vivo studies on the metabolism of T2 and HT2 in humans are available, but data from in vitro
experiments indicate that the same metabolic pathways as observed for T2 and HT2 in animal studies
operate in humans. After incubation of T2 with primary renal proximal tubule epithelial cells, primary
human lung ﬁbroblasts or HT-29 cells (a cell line derived from human colon carcinoma cells), several of
the hydrolytic and monohydroxylated T2 metabolites (as shown in Figure 2) were identiﬁed using
LC–MS (Weidner et al., 2012). HT2 and NEO were the major metabolites, whereas minor amounts of
19-hydroxy-T2, T2-triol, and 4-deacetyl-NEO were detected.
7.3.2. Phase II metabolism
The glucuronides of T2 and HT2, which appear to be the most prevalent mammalian phase II
metabolites of these toxins, are listed in Table 2 of Section 4. Several older in vivo and in vitro studies
in animals provide indirect evidence for the formation of glucuronides of T2, HT2, 3-hydroxy-T2 and
3-hydroxy-HT2 by demonstrating the release of the respective aglycones from a polar metabolite
fraction, assumed to represent glucuronides, upon treatment with the enzyme b-glucuronidase
(reviewed by Weidner et al., 2012). More recently, LC–MS together with reference compounds has
been used to identify T2-GlcA and HT2-3-GlcA in two human cell types after incubation with T2
(Weidner et al., 2012). When hepatic microsomes of rat, mouse, pig and human were incubated with
T2 in the presence of uridine 50-diphospho-glucuronic acid (UDPGA) and the pattern of glucuronides
determined by LC–MS/MS, human microsomes exhibited a higher activity for glucuronidation than
rodent or pig microsomes. Of the two regioisomers of HT2-GlcA, the 3-isomer was exclusively formed
in rat, mouse and human microsomes, and only pig hepatic microsomes generated both isomers. A
mixture of HT2-3-GlcA and HT2-4-GlcA was also demonstrated in the urine of female pigs dosed orally
or by intravenous (i.v.) injection with T2 (Weidner et al., 2012).
7.4. Excretion
No study on the excretion of T2 or HT2 or their metabolites has been published since 2011. As
stated in the previous EFSA opinion, animals rapidly excrete T2 and its metabolites in urine and faeces,
mainly as glucuronides, with the urine to faeces ratio depending on the species (EFSA CONTAM Panel,
2011; Welsch and Humpf, 2012). For example, almost all the radioactivity after a single dose of
tritium-labelled T2 given by intubation was excreted by a lactating cow within 72 h (Yosizawa et al.,
1981); urinary excretion was completed after 48 h and accounted for 30% of the dose. Similar results
were obtained after a single oral dose of tritium-labelled T2 administered to mice or rats (Matsumoto
et al., 1978; Pfeiffer et al., 1988). In guinea pigs, 75% of the radioactivity was excreted in the urine
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and faeces at a ratio of 4 to 1 after 5 days, albeit after a single intramuscular injection of tritiated T2
(Pace et al., 1985).
8. Toxicity
8.1. In vivo toxicity data on T2 an HT2
8.1.1. Study used for establishing the TDI by EFSA 2011
In their previous opinion (EFSA CONTAM Panel, 2011), the Panel concluded that T2 induces
haemato- and myelotoxicity, and noted that T2 was positive in some clastogenicity tests but mainly at
concentrations known to inhibit protein and DNA synthesis and produced cytotoxicity. The
Panel concluded at that time that T2 inhibited protein-, DNA- and RNA synthesis and that there were
studies indicating that T2 causes apoptosis, necrosis and lipid peroxidation.
A subacute study (21 days) with pigs (Rafai et al., 1995) was identiﬁed as the most appropriate
one to derive a HBGV for T2 despite the shortness of the study and the fact that the purity of T2 was
only 90%. The toxin was prepared by fermentation of Fusarium tricinctum. The calculated amount of
T2 was used to prepare a corn meal-based premix, which was then added to the daily ration. Nine to
ten piglets per group (gender not reported, mean weight of animals at beginning of study about 9 kg)
were fed diets containing 0, 0.5, 1, 2 or 3 mg T2/kg diet (average daily feed intakes were 0, 0.38,
0.81, 1.24 and 1.43 mg, respectively) over a period of 21 days, resulting in doses of 0, 29, 62, 105 or
129 lg T2/kg bw per day, respectively. The CONTAM Panel noted that in this study the feed intake
was decreased signiﬁcantly (by 13%) already at the lowest dose which was also reﬂected in the
decreased bodyweight gain observed. No pair fed controls was investigated, which might have led to
biased observations of other effects. Decreased stimulation of lymphocytes by concanavalin A (ConA),
decreased leucocyte and T-cell counts as well as reduced anti-horse immunoglobulin titre and
histological changes in the thymus, spleen and lymph nodes were observed. Reduction in antibody
response to a speciﬁc antigen was identiﬁed as the critical effect for human risk assessment (a LOAEL
of 29 lg T2/kg bw per day was identiﬁed while no NOAEL could be identiﬁed in this study) and used
for a BMD analysis. A BMDL05 of 10 lg T2/kg bw per day was established. Since T2 is rapidly
metabolised to HT2 and the toxicity of T2 might at least partly be attributed to HT2, a group TDI of
0.1 lg/kg bw per day was established for the sum of T2 and HT2 by applying an UF of 100 to
the BMDL05.
8.1.2. In vivo toxicity studies with T2 and HT2 toxin published after 2011
The following subchapters provide an overview on oral in vivo studies with T2 and HT2 published
after publication of the EFSA opinion of 2011. When the doses tested were reported only in mg/kg
diet, they have been calculated to mg/kg bw per day according to respective EFSA guidances
(EFSA FEEDAP Panel, 2012; EFSA Scientiﬁc Committee, 2012).
8.1.2.1. Acute toxicity studies
Mice
Wu et al. (2015) used a mouse model to compare the anorectic potencies of T2 with HT2. Groups
of six female B6C3F1 mice were dosed with 0, 0.01, 0.1, 0.5 and 1 mg T2 or HT2/kg bw by single oral
gavage and were then immediately given preweighed food pellets. Food intakes were measured 0.5, 1,
2, 3, 6, 16, 24 and 48 h after exposure. T2 and HT2 induced anorectic responses (marked reduction in
feed consumption) that lasted up to 48 h. The authors identiﬁed a LOAEL of 0.1 mg/kg bw and a
NOAEL of 0.01 mg/kg bw for both compounds. It is notable that, when the animals were administered
T2 and HT2 at the same doses intraperitoneal (i.p.), anorectic responses were induced at the same
dose (LOAEL of 0.1 mg/kg bw) lasting up to 96 h after injection.
Mink
Fasted female mink (Neovison vison, four animals/group) were administered T2 or HT2 (0, 0.001,
0.01, 0.05 and 0.25 mg/kg bw) (experiment 1) or emetine (0, 0.5, 1, 2.5 and 5 mg/kg bw) by i.p.
injection, and T2 or HT2 (0, 0.005, 0.05, 0.25 and 0.5 mg/kg bw) or emetine (0, 0.5, 1, 2.5 and
5 mg/kg bw) (experiment 2) by oral gavage (Wu et al., 2016). Thirty minutes before gavage, 50 g of
feed were given to the animals. Then they were monitored for emetic events for 3 h. During this
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period, the incidence of emesis, the latency to emesis, duration of emesis and the number of emetic
events were screened. An emetic event was described as either vomiting or retching. Wu et al. (2016)
deﬁned vomiting as a rhythmic abdominal contraction with oral expulsion of solid or liquid material.
Retching is deﬁned as a reaction that mimicked vomiting but without voiding material. Latency to
emesis is the time from application of the substance to the ﬁrst emetic event. Emesis duration is the
time from the ﬁrst until the last emesis. The lowest dose that induced an emetic response by oral
dosing was 0.05 mg/kg bw with an incidence of three out of four animals for both T2 and HT2. At all
the effective doses, both retching and vomiting took place, with retching as the more frequent event
occurring. Following i.p. administration the incidence was lower, one out of four animals at the same
dose. Emetic events occurred in four animals at a dose of 0.25 mg/kg bw by both administration
routes. The latency decreased while duration and frequency of emetic events increased with dose. Oral
administration of T2 and HT2 elicited marked elevations in plasma concentrations of the anorectic
peptide pancreatic peptide YY3-36 (PYY3-36) and 5-hydroxytryptamine (5-HT), hormones known to be
implicated in emesis. According to the authors the effective dose (ED) resulting in emetic events in
50% (ED50) of the animals for oral exposure to T2 and HT2 was 30 lg/kg bw.
For the ipecacuanha alkaloid emetine, that was used as a positive control in this study. The ED50
was 1.03 mg/kg bw. Emetine is a major alkaloid in ipecacuanha syrup, which has been used to induce
vomiting in humans. The dose of emetine effective in humans is in the same range as that given to
the mink and the mink has been suggested to be used as a model for emesis in drug testing (Gordon,
1985; Zhang et al., 2006; Percie du Sert et al., 2012). The CONTAM Panel therefore concludes that the
mink is an appropriate animal model to investigate vomiting in humans.
8.1.2.2. Subacute toxicity studies
Rats
T2 (20 mg/kg feed, equivalent to 2.4 mg/kg bw per day) was fed to groups of six male Wistar rats
for 14 days (Chandratre et al., 2014). Animals showed signiﬁcant haematological alterations (total
thrombocyte count was 2.6 9 103/lL compared to 17.07 9 103/lL in controls; total leucocyte count
was 1.29 9 103/lL compared to 14.17 9 103/lL in controls) and increased levels of biological markers
of oxidative stress with concomitant decrease in levels of serum and tissue catalase and superoxide
dismutase were observed which were associated with histopathological changes. No residual T2 was
detected in any of the organs tested, suggesting that T2 does not accumulate in tissues even at such
a high exposure level.
Kashin–Beck disease (KBD) is an endemic degenerative osteoarthropathy that has been observed in
selenium-deﬁcient areas and is supposedly connected to T2 and HT2 exposure. The mechanisms
underlying its pathogenesis remain unclear. Since publication of the EFSA opinion on T2 and HT2
(EFSA CONTAM Panel, 2011) several subacute studies have been carried out to elucidate the
pathogenesis of this disease (Chen et al., 2012; Guan et al., 2013; Kang et al., 2013). The CONTAM
Panel noted that these new studies are not suitable for hazard characterisation of T2/HT2 and are
therefore not presented.
Pigs
Obremski et al. (2013) administered doses of 10 lg T2/kg bw per day to piglets for 42 days. Ileum
sections were collected on days 14, 28 and 42. After 42 days, a signiﬁcant drop in the messenger RNA
(mRNA) level of interleukin (IL)-10 in ileal Peyer’s patches was observed. A gradual, non-signiﬁcant
decrease in the amount of IL-4 and interferon (IFN)-gamma cytokine transcripts was found throughout
the experiment. On days 14 and 42, a signiﬁcant increase in the percentage of cluster of
differentiation (CD)8+ T lymphocytes was observed, while it was decreased on day 28. Percentage of
CD21+ B cells in the treated animals group decreased steadily and was signiﬁcant on days 28 and 42.
On days 14 and 28, the percentages of CD4+ and CD8+ T lymphocytes were lowered in the
experimental animals as compared with the control group, reaching statistical signiﬁcance on day 28.
The CONTAM Panel noted that only one dose level was tested in this study and that there is no clear
evidence that the effects observed were related to adversity.
Three groups of 10 growing pigs were fed for 21 days diets containing 0, 0.3 and 0.5 mg T2/kg
feed equal to 0, 11.5 and 18.6 lg T2/kg bw per day (Rafai et al., 2013). T2 was prepared by the
fermentation of F. tricinctum (NRLL 3299) in a liquid medium. T2 signiﬁcantly impaired feed intake and
growth rate of pigs. Mean daily weight gains were 497, 377 and 317 g for control, low and high dose,
respectively. Neither treatment level of T2 caused consistent nor signiﬁcant changes in the metabolic,
Group HBGV for T2 and HT2 and their modiﬁed forms
www.efsa.europa.eu/efsajournal 22 EFSA Journal 2017;15(1):4655
immunological and other blood parameters tested. The authors suggest that the considerably lower T2
intake due to feed refusal seen in this study might explain that immunotoxicity was not observed
unlike in their previous study (Rafai et al., 1995).
8.1.2.3. Subchronic toxicity studies
Rats
Raut et al. (2013) fed rats with feed containing 0, 0.25, 0.50 and 0.75 mg/kg T2, respectively
(equivalent to 0, 23, 45 and 68 lg T2/kg bw per day, respectively) for 90 days. A signiﬁcant,
dose- and duration-dependent thrombocytopenia was observed. Mean thrombocyte counts were
reduced with increasing dose. Total erythrocyte counts and total leucocyte counts were reduced, albeit
not statistically signiﬁcantly. The non-statistically signiﬁcant reduction in total leucocyte counts was
attributed by the authors to lymphocytopaenia as (not statistically signiﬁcant) decreases in the
proportion of lymphocytes of the total leucocyte counts were observed. Hypoproteinaemia was
diagnosed (reduced level of albumin and globulin paralleled by increased alanine amino transferase
(ALT), aspartate amino transferase (AST) activities and creatinine levels). Alkaline phosphatase (ALP)
activity was reduced at higher doses. The liver and kidneys were pale and slightly enlarged in animals
at the highest dose. The relative liver, kidney and brain weight increased while the testes, thymus and
spleen weights were reduced. Lipid peroxidase (LPO) activity was increased whereas superoxide
dismutase (SOD) and catalase activities decreased. The CONTAM Panel did not identify a NOAEL in this
study and considered the lowest dose tested (23 lg/kg bw per day) as a LOAEL. The Panel noted that
while the decrease in total thrombocyte counts is in line with ﬁndings in other studies, the absence of
signiﬁcant effects on total leucocyte count and total erythrocyte count is not. In addition, the CONTAM
Panel noted that the reporting of units for blood cell count in this study is unclear. Therefore, it was
decided not to consider this study for hazard characterisation.
Rahman et al. (2014) gave feed containing 0, 0.5, 0.75 and 1 mg T2/kg (equivalent to 0, 45, 68
and 90 lg T2/kg bw per day, respectively) to male Wistar rats (48 per group) via the diet, daily for a
period of up to 12 weeks. Subgroups of eight animals were sacriﬁced after 2, 4, 6, 8, 10 and
12 weeks. Cultures of F. sporotrichioides var. sporotrichioides MTCC 1894, were utilised to produce T2
on partially ground maize and intact wheat grains. In rats treated for 90 days, a statistically signiﬁcant
dose-dependent decrease in body weights was seen. Mean body weights were 264, 219, 183 and
159 g in groups applied 0, 45, 68 and 90 lg T2/kg bw per day, respectively. Signiﬁcant decreases in
haemoglobin, packed cell volume, total erythrocyte, total thrombocyte and total leucocyte counts,
mean corpuscular volume (MCV), mean corpuscular haemoglobin, and percentages of lymphocytes
were observed while the percentage of neutrophils increased. Overall, all these observations became
more pronounced with study length. At the end of the study, the mean total erythrocyte count levels
were 8.97, 5.85, 5.77, 4.65 9 106/lL in animals treated with 0, 45, 68 and 90 lg T2/kg bw per day,
respectively, mean total leucocyte count levels were 14.83, 8.95, 6.92 and 5.20 9 103/lL for groups
receiving 0, 45, 68 and 90 lg T2/kg bw per day, respectively, and mean total thrombocyte count levels
were 123, 78, 57 and 38 9 103/lL in groups treated with 0, 45, 68 and 90 lg T2/kg bw per day,
respectively. Overall, the authors concluded that in rats, T2 induces microcytic hypochromic anaemia
and leukocytopaenia (due to lymphocytopaenia) and thrombocytopenia increasing with dose and
duration of exposure. The Panel did not identify a NOAEL in this study and considered the lowest dose
tested (45 lg/kg bw per day) as a LOAEL. The Panel noted that the adverse effects observed in this
study (microcytic hypochromic anaemia, leukocytopaenia, and thrombocytopenia) are not only
consistent with those of previously published in vitro and in vivo studies (see EFSA CONTAM Panel,
2011) but also that the total thrombocyte count values reported in the study are unusually low. The
Panel noted that the purity of the substance was not speciﬁed and nominal concentrations reported
might not correspond to those actually tested. Furthermore, it cannot be excluded that other
mycotoxins were present in the tested material limitations that also apply to the studies of Raut et al.
(2013) and Rafai et al. (1995), the latter used for establishment of a TDI in 2011.
8.1.2.4. Developmental toxicity studies
Mice
Tanaka et al. (2016) investigated the effects of T2 on post-natal hippocampal neurogenesis in mice.
Dams were given T2 at 0, 1, 3 or 9 mg/kg in the diet from gestation day (GD) 6 to day 21
corresponding to exposures of 0, 0.14, 0.40 and 1.18 mg T2/kg bw per day during gestation and to 0,
0.49, 1.39 and to 3.79 mg T2/kg bw per day during lactation. Offspring were maintained through
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postnatal day (PND) 77 without T2 exposure. At PND 21, changes in the hippocampus paralleled with
increased apoptosis were seen in male offspring of dams of the two highest dose groups and reduced
relative brain weight was seen in male offspring of dams treated with the highest dose. Neurogenesis-
related changes disappeared on PND 77, suggesting that T2 reversibly affects neurogenesis by
inducing apoptosis. The authors identiﬁed a NOAEL of 140–490 lg/kg body weight per day for effects
of T2 on offspring neurogenesis.
8.1.2.5. Concluding remarks
New acute toxicity and subacute studies on anorectic effects (e.g. feed refusal, retching, vomiting,
reduced body weight gain) at low doses in several species (mouse, mink and pig) have become
available, indicating that there is a need for establishing an ARfD. In this context, it is noted that
nausea and emesis has been reported in humans consuming mouldy grain contaminated with T2
producing strains of Fusarium poae and F. sporotrichoides (EFSA CONTAM Panel, 2011).
The Panel concluded that the new subchronic toxicity studies investigating similar endpoints but in
longer term studies than those performed in pigs and used as a basis in the previous assessment,
conﬁrmed immuno- and haematotoxicity of T2 and HT2 (see also EFSA CONTAM Panel, 2011).
8.2. Toxicity data on modiﬁed forms of T2 and HT2
For this section, all available relevant literature has been considered (i.e. also publications prior to
2011).
8.2.1. In vivo toxicity of phase I metabolites
Only few in vivo studies evaluating the toxicity of phase I metabolites relative to T2 and HT2 were
identiﬁed. All studies were acute toxicity studies and are presented in Table 4. In order to compare the
toxic potency of the different metabolites to that of T2, the effective dose of each metabolite has been
expressed on a molar basis, and the effective molar dose of T2 has been set to 1 for all studies.
Table 4: In vivo acute toxicity studies comparing the toxicity of T2 and their phase I metabolites
Species/
administration
Endpoint/dose range
Effective molar doses
relative toxicity)(a)
Reference
Ducklings/s.c. Minimum emetic dose/dose
range not reported
T2: 0.21 lmol/kg bw (1)
HT2: 0.24 lmol/kg bw (0.88)
NEO: 0.26 lmol/kg bw (0.81)
Ueno et al. (1974)
Broiler chicks/p.o. LD50/7 doses per dose range
6.2–18.7 lmol/kg bw
7.1–32.5 lmol/kg bw
26.2–127 lmol/kg bw
26.2–110 lmol/kg bw(b)
33.6–235 lmol/kg bw
T2: 10.7 lmol/kg bw (1)
HT2: 17.0 lmol/kg bw (0.63)
NEO: 65.1 lmol/kg bw (0.16)
T2-triol: 79.0 lmol/kg bw (0.14)
T2-tetraol: 113 lmol/kg bw (0.094)
Chi et al. (1978)
Male mice/i.p. LD50/dose range not reported T2: 11.2 lmol/kg bw (1)
HT2: 21.2 lmol/kg bw (0.53)
NEO: 38.0 lmol/kg bw (0.29)
T2-triol: 283 lmol/kg bw (0.04)
Ueno et al. (1986)
Female mice/i.v. Induction of apoptosis in
thymus cells (%DNA
fragmentation above negative
control (2%)/dose of 1.56 mg
toxin/kg bw
T2 (3.35 lmol/kg bw): 22% (1)
HT2 (3.68 lmol/kg bw): 3% (0.14)
19-HO-T2(c) (3.24 lmol/kg bw):
24% (1.1) 19-HO-HT2(c)
(3.55 lmol/kg bw) 4% (0.2) NEO
(4.05 lmol/kg bw): 0.5% (0.023)
T2-tetraol (5.23 lmol/kg bw): 0%
Islam et al. (1998)
bw: body weight; i.p.: intraperitoneal; i.v.: intravenous; p.o.: per os; s.c.: subcutaneous; LD50: median lethal dose; NEO:
neosolaniol.
(a): Relative toxicity (doses have been converted from weight to moles and the effective molar dose has been set as 1 for T2).
(b): Only three doses tested.
(c): In the original paper (Islam et al., 1998), these compounds were designated as 30-HO-T2 and 30-a)HO-HT2 due to a different
numbering system.
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In 1974, Ueno and co-workers showed that the minimal subcutaneous (s.c.) dose of trichothecenes
to induce vomiting in ducklings is 0.1 mg/kg bw for T2, HT2 and NEO.
Acute toxic effects of T2, HT2, NEO, T2-triol, and T2-tetraol were investigated in 1-day-old broiler
chicks by applying single oral doses (Chi et al., 1978). According to the authors, the results of the
present study and previous reports indicate that T2 is metabolised into less toxic compounds when
consumed by chickens.
The median lethal dose (LD50) values of T2, HT2, NEO and T2-triol were estimated by a single i.p.
injection of toxins to male mice. Macroscopic observation revealed severe haemorrhage in the intestine
and lung (Ueno et al., 1986).
Islam et al. (1998) investigated the effects of T2-derived metabolites on induction of apoptosis of
thymus cells in vivo in mice. The ranking order of apoptosis-inducing activity was found to be
T2 = 19-HO-T2 > HT2 = 19-HO-HT2 > NEO = T2-tetraol = control. The authors concluded that both
the acetyl group at C-4 position and the isovaleroyl or 19-hydroyisovaleroyl group at the C-8 position
of T2 appear to be involved in thymic apoptosis.
In addition, Chattopadhyay et al. (2013) evaluated the haematotoxicity of T2 and NEO in Sprague–
Dawley rats and observed inter alia signiﬁcant decreases in white blood cell and red blood cell count
upon application of T2 and NEO (data not shown in Table 4). Based on unclear reporting of the
experiments and the fact that baseline levels of some blood cell counts in control groups deviated
strongly from those usually reported in rats, the CONTAM Panel decided not to consider the results of
the study.
8.2.1.1. Concluding remarks
The CONTAM Panel identiﬁed only few in vivo studies in which the acute toxicity of modiﬁed T2 and
HT2 (only phase I metabolites) was compared with T2 and HT2. Endpoints investigated were acute
lethality, induction of apoptosis in thymus cells and vomiting. In most instances, all metabolites tested
exerted these effects and were equally or less potent than T2 or HT2.
8.2.2. In vitro toxicity of phase I metabolites
T2 has been described to be cytotoxic to a range of blood cells (white blood cell progenitors,
platelet progenitors, red blood cell progenitors, red blood cells) from different species (human, rat,
guinea pig) at concentrations of 5.4 nM or higher (see EFSA CONTAM Panel, 2011).
Furthermore, T2 has been reported to inhibit the transpeptidation of peptide formation at the
60S ribosomal subunit by inhibiting the peptidyl transferase (EFSA CONTAM Panel, 2011).
Concentrations of T2 exceeding 6 nM resulted in induction of apoptosis in a range of different cell lines
(EFSA CONTAM Panel, 2011).
Table 5 summarises the identiﬁed in vitro studies on the toxicity of T2/HT2 and its phase I
metabolites. Both studies already described in EFSA CONTAM Panel (2011) as well as more recent
studies are included. For each of the different phase I metabolites, its relative molar toxicity with
respect to T2 is given in each study (potency of T2 set as 1).
Some of the compounds are hypothetical metabolites, i.e. they could be formed according to
metabolic considerations but have not yet been detected as naturally occurring metabolites. Such
compounds have been chemically synthesised and are included in Table 5 to obtain a broader basis for
structure–activity relationships.
Table 5: In vitro toxicity studies with T2 and HT2 and its phase I metabolites in various cell systems
Cell system Endpoint
Effective concentrations
(relative molar toxicity)(g)
Reference
Primary human
lymphocytes
Inhibition of mitogen-induced
blastogenesis; 72-h exposure;
EC50
T2: 3.2 nM (1)
HT2: 8.3 nM (0.39)
T2-triol: 390 nM (0.008)
T2-tetraol: 500 nM (0.006)
19-Hydroxy-T2: 8.3 nM (0.39)
19-Hydroxy-HT2: 115 nM (0.028)
Forsell et al. (1985)
Kidney epithelial cell line
(Vero cells, African green
monkey)
Inhibition of protein synthesis
(3H-leucin incorporation); 1-h
exposure; EC50
T2: 24 nM (1)
*Acetyl-T2: 19,500 nM (0.0012)
T2-tetraol: 22,800 nM (0.0011)
Ehrlich and Daigle (1985)
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Cell system Endpoint
Effective concentrations
(relative molar toxicity)(g)
Reference
Mouse erythroleukaemia
cell line
Inhibition of protein synthesis
(3H-leucin incorporation), 1-h
exposure; EC50
T2: 6 nM (1)
*Acetyl-T2: 3,500 nM (0.0017)
T2-tetraol: 6,400 nM (0.00094)
Ehrlich and Daigle (1985)
Kidney epithelial cell line
(Vero cells, African green
monkey)
Inhibition of protein synthesis
(3H-leucin incorporation): 1.5 h
exposure; EC50
T2: 14 nM (1)
HT2: 65 nM (0.22)
NEO: 273 nM (0.051)
T2-triol: 1,120 nM (0.013)
T2-tetraol: 5,856 nM (0.0024)
*Acetyl-T2: 5,792 nM (0.0024)
Thompson and
Wannemacher (1986)
Primary rat spleenocytes Inhibition of protein synthesis
(3H-leucin incorporation); 1.5-h
exposure; EC50
T2: 6 nM (1)
HT2: 10 nM (0.60)
NEO: 127 nM (0.047)
T2-triol: 151 nM (0.040)
T2-tetraol: 7,832 nM (0.0008)
*Acetyl-T2: 1,036 nM (0.006)
Thompson and
Wannemacher (1986)
Rabbit reticulocytes Inhibition of protein synthesis
(3H-leucin incorporation); 1.5-h
exposure; EC50
T2: 21.5 nM (1)
HT2: 70.8 nM (0.30)
NEO: 654 nM (0.033)
T2-triol: 5,240 nM (0.004)
T2-tetraol: 8,390 nM (0.002)
Ueno et al. (1986)
Tetrahymen pyroformis Inhibition of protein synthesis
(3H-leucin incorporation); 1.5-h
exposure; EC50
T2: 53.6 nM (1)
HT2: 118 nM (0.45)
NEO: 1,310 nM (0.041)
T2-triol: 5,240 nM (0.010)
T2-tetraol: 8,390 nM (0.006)
Ueno et al. (1986)
Human acute
promyelocytic leukaemia
cell line (HL 60)
Cell viability (trypan blue
exclusion);concentrations
required to kill 100% of the
cells in 5 days
T2: 17 nM (1)
HT2: 19 nM (0.89)
NEO: 340 nM (0.050)
T2-triol: 262 nM (0.065)
T2-tetraol: 470 nM (0.036)
*Acetyl-T2: 39 nM (0.44)
*9,10-Epoxy-T2: 207 nM (0.082)
*9,10-Dihydro-T2: 280 nM (0.061)
Samara et al. (1987)
Brine shrimp (Artemia
salina) bioassay
Cytotoxicity; 24-h exposure of
eggs; lethality of hatched
shrimps; LC50
T2: 240 nM (1)
HT2: 610 nM (0.39)
T2-triol: 3,600 nM (0.067)
T2-tetraol: 3,200 nM; (0.075)
De-epoxy-HT2: > 14,700 nM (< 0.016)
De-epoxy-T2-triol: > 13,700 (< 0.018)
De-epoxy-T2-tetraol: > 21,300 (< 0.011)
Swanson et al. (1987)
Adult human liver cell line
(Chang liver)
Cell viability; 6-day exposure;
amido black 10B; EC50
T2: 5 nM (1)
HT2: 10 nM (0.50)
NEO: 200 nM (0.025)
T2-triol: 105 nM (0.048)
T2-tetraol: 800 nM (0.0062)
*Iso-T2(a): 49 nM (0.10)
*Acetyl-T2: 26 nM (0.19)
*Tetraacetyl-T2-tetraol: 150 nM (0.033)
*4,8-Diacetyl-T2-tetraol(b): 110 nM (0.045)
von Milczewski (1987)
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Cell system Endpoint
Effective concentrations
(relative molar toxicity)(g)
Reference
Human epidermoid
carcinoma cell line (HEp-2)
Cell viability; 6-day exposure;
amido black 10B; EC50
T2: 5 nM (1)
HT2: 10 nM (0.5)
NEO: 180 nM (0.028)
T2-triol: 86 nM (0.058)
T2-tetraol: 670 nM (0.0075)
*Iso-T2(a): 59 nM (0.017)
*Acetyl-T2: 16 nM (0.31)
*Tetraacetyl-T2-tetraol: 150 nM (0.033)
*4,8-Diacetyl-T2-tetraol(b): 86 nM (0.058)
von Milczewski (1987)
Girardi human heart cell
line (clone GHc7)
Cell viability; 6-day exposure;
amido black 10B; EC50
T2: 9 nM (1)
HT2: 12 nM (0.75)
NEO: 210 nM (0.043)
T2-triol: 76 nM (0.12)
T2-tetraol: 470 nM (0.019)
*Iso-T2(a): 28 nM (0.32)
*Acetyl-T2: 70 nM (0.13)
*Tetraacetyl-T2-tetraol: 100 nM (0.090)
*4,8-Diacetyl-T2-tetraol(b): 400 nM (0.023)
von Milczewski (1987)
Pig kidney cell line (clone
Amc6sc8)
Cell viability; 6-day exposure;
amido black 10B; EC50
T2: 10 nM (1)
HT2: 11.3 nM (0.88)
NEO: 3–6 nM (3.33–1.67)(c)
T2-triol: 39 nM (0.26)
T2-tetraol: 540 nM (0.019)
*Iso-T2(a): 3.4 nM (2.94)
*Acetyl-T2: 50 nM (0.20)
*Tetraacetyl-T2-tetraol: 9.4 nM (1.06)
*4,8-Diacetyl-T2-tetraol(b): 6 nM (1.67)
von Milczewski (1987)
Mouse lymphoma cell line
(L5178Y)
Cell viability; 3-day exposure;
EC50
T2: 3.9 nM (1)
HT2: 7.1 nM (0.55)
NEO: 105 nM (0.037)
T2-triol: 260 nM (0.015)
T2-tetraol: 340 nM (0.012)
*Iso-T2(a): 43 nM (0.090)
*3-Acetyl-T2: 40 nM (0.097)
*8-Acetyl-NEO: 3.2 nM (1.22)
*3-Acetyl-NEO: 47 nM (0.083)
*Tetraacetyl-T2-tetraol: 43 nM (0.091)
*3,4,8-Triacetyl-T2-tetraol: 190 nM (0.021)
*4,8-Diacetyl-T2-tetraol(b): 160 nM (0.024)
*15-Deacetyl-NEO(d): 60 nM (0.065)
Anderson et al. (1989)
Human ﬁbroblast cell line
(GM5757)
Cell viability; 48-h exposure;
MTT(e) assay; EC50
T2: 122 nM (1)
HT2: 383 nM (0.32)
NEO: 342 nM (0.36)
T2-tetraol: 6,540 nM (0.019)
*Acetyl-T2: 1,970 nM (0.062)
Kim et al. (1991)
Human liver cell line
(HepG2)
Cell viability, 48-h exposure;
neutral red uptake; EC50
T2: 21 nM (1)
HT2: 37 nM (0.57)
T2-triol: 1,040 nM (0.020)
T2-tetraol: 1,490 nM (0.014)
Babich and
Borenfreund (1991)
Baby hamster kidney cell
line (BHK-21 cells)
Cytotoxicity; 24-h exposure;
approximate LC100
T2: 10.7 nM (1)
HT2: 240 nM (0.045)
NEO: 26.2 nM (0.41)
T2-tetraol: 33,500 nM (0.0003)
19-Hydroxy-T2: 10.3 nM (1.03)
*8-Acetyl-T2-tetraol: 294,000 nM (0.00004)
*4,8-Diacetyl-T2-tetraol(b): 2,620 nM (0.0041)
*8-Acetyl-NEO: 1,180 nM (0.009)
Senter et al. (1991)
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8.2.2.1. Concluding remarks
The studies listed in Table 5 support the data presented in EFSA CONTAM Panel (2011). The
various phase I metabolites exhibit considerable differences in their toxic activity at two endpoints, viz.
inhibition of protein synthesis and cell viability. Most data were available for the metabolites formed
through consecutive hydrolysis of the ester groups of T2, i.e. HT2, NEO, T2-triol and T2-tetraol, while
data on other phase I metabolites were very scarce or lacking. In vitro activity was always highest for
T2. For the hydrolytic metabolites, HT2 was almost as active as T2, while NEO and T2-triol were less
active, and T2-tetraol invariably exhibited the lowest toxicity. Hydroxylation of T2 at C-19 had no
signiﬁcant effect on T2 toxicity. Thus, the ranking of toxicity derived from the in vitro studies (Table 5)
is consistent with the ranking from in vivo studies (Table 4). For the other metabolites in Table 5, no
clear ranking emerges from the few available studies.
8.2.3. Toxicity of phase II metabolites
The CONTAM Panel did not identify toxicity studies with phase II metabolites (e.g. glucosides,
sulfates, glucuronides) of parent T2 and HT2 or from their phase I metabolites.
9. Mode of action for toxicity of T2 and HT2 toxins and their
metabolites
Most of the data on the biochemical mode of action are concerning T2 with fewer studies available
for HT2. The mode of action of T2 and HT2 has been reviewed review in the previous EFSA opinion
(EFSA CONTAM Panel, 2011). The following chapter will brieﬂy summarise the major ﬁnding and
discuss in more detail pertinent studies since 2011.
9.1. Induction of ribotoxic stress and effect on nucleic acids
As other trichothecenes, T2 is a protein synthesis inhibitor known to target ribosome and binds to
the 60S subunit of the ribosome. Recent crystallographic analysis show that the trichothecene DON
more speciﬁcally targets the site A of the peptidyl transferase centre (Garreau de Loubresse et al.,
2014). Binding to ribosomes, T2 interferes with the elongation step of protein synthesis, more
speciﬁcally with the peptide bond formation (Garreau de Loubresse et al., 2014).
Cell system Endpoint
Effective concentrations
(relative molar toxicity)(g)
Reference
Primary human renal
proximal tubule epithelial
cells
Cell viability; 48-h exposure;
CCK-8(f) assay; EC50
T2: 200 nM (1)
HT2: 800 nM (0.25)
NEO: 3,000 nM (0.067)
T2-triol: 14,600 nM (0.014)
T2-tetraol: 25,100 nM (0.008)
K€onigs et al. (2009)
Primary human lung
ﬁbroblasts
Cell viability; 48-h exposure;
CCK-8(f) assay; EC50
T2: 500 nM (1)
HT2: 700 nM (0.71)
NEO: 2,000 nM (0.25)
T2-triol: 10,600 nM (0.047)
T2-tetraol: 8,300 nM (0.060)
K€onigs et al. (2009)
Lung ﬁbroblast cell line
from male Chinese
hamster (V79)
Cell viability; 48-h exposure;
neutral red uptake; EC50
T2: 3 nM (1)
HT2: 14 nM (0.21)
Behm et al. (2012)
RPF: relative potency factor with respect to T2; EC50: Half-maximal effective concentration; LC: left-censored; NEO: neosolaniol.
(a): Also designated as 3-acetyl-HT2.
(b): Also designated as NT-1 toxin.
(c): Considered an outlier (only range given, very different from results of numerous other studies on NEO).
(d): Also designated as NT-2 toxin.
(e): MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
(f): Cell Counting Kit-8, using reduction of 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt.
(g): The doses used have been recalculated from weight to molar units. Relative toxicity (effective molar dose) has been set as 1 for T2.
*: Hypothetical metabolite (i.e. not identiﬁed occurring naturally).
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Transcriptomic analysis revealed that of the total genes affected by T2, 20% were related to
transcription and 30% to translation pathways. Speciﬁcally, T2 reduces the activities of aminoacyl-tRNA
synthetases and adversely affects the translation initiation. The protein processing and folding are also
inﬂuenced by T2 through the declined levels of sulfhydryl oxidases, disulﬁde isomerases and heat
shock protein 90 (Hsp90) (Wan et al., 2015a).
Ribosome binding by T2 quickly activates mitogen-activated protein kinase (MAPK) via a mechanism
known as the ‘ribotoxic stress response’ (Yang et al., 2000; Wan et al., 2015b). MAPKs are important
transducers of downstream signalling events related to immune response and apoptosis. T2 activates
several MAPKs including p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1
and 2 (ERK1/2).
DNA and RNA synthesis are also inhibited by T2; this could be secondary to the inhibition of protein
synthesis (Rakkestad et al., 2010). Inhibition of DNA, synthesis by T2 has been reported at
concentrations generally exceeding those that cause an inhibition of protein synthesis (EFSA CONTAM
Panel, 2011).
9.2. Apoptosis
T2 also causes apoptosis in vitro in various cell types and in vivo in lymphoid organs, intestinal
crypt, brain, skin and fetal tissues (EFSA CONTAM Panel, 2011). Apoptosis has been conﬁrmed by
histology, in situ detection of fragmented DNA, DNA agarose gel electrophoresis and ﬂow cytometry.
As far as circulating blood cells are concerned, apoptosis of haematopoietic progenitors by T2,
blocks the renewal of blood cells in the bone marrow. As the life time of leucocytes and platelets
(approximately 10 days in humans) is shorter than the life time of red blood cells (120 days in
humans), the most common symptom observed are decrease in leucocyte and thrombocytes count in
circulating blood cells inducing leucopoenia and thrombocytopenia and increasing the risk of
septicaemia and haemorrhage.
In vitro, T2 induced apoptosis has been associated with activation of several caspases, increased
expression of genes involved in apoptosis such as c-Jun and c-fos, p53 and Bax and in some studies
the decrease in the anti-apoptotic factor Bcl-xL (EFSA CONTAM Panel, 2011).
The mechanisms of T2 induced apoptosis have been controversially discussed and it has been
hypothesised that DNA damage may be a secondary effect of the protein synthesis inhibition or oxidative
stress that can in turn activate mitochondrial apoptotic pathways upon exposure to T2 and that apoptosis
could be related to the induction of stress-activated protein kinase (SAPK/JNK) and mitogen-activated
protein kinase (p38/MAPK) (Jaradat, 2005; EFSA CONTAM Panel, 2011; Wu et al., 2014).
9.3. Effects on membranes and oxidative stress
T2 is an amphophilic molecule, taken up into the cells bilayer membrane. It may then induce lipid
peroxidation by generating free radicals, and thereby damaging cellular membranes. There is still some
inconsistency among the results shown for the T2 mediated effects on oxidative stress markers. While
several studies showed increased malondialdehyde (MDA) levels, others reported no changes. The
extent to which reactive oxygen species (ROS) contribute to the clastogenicity and DNA strand breaks
observed in some tests but not in others as reported in the previous opinion (EFSA CONTAM Panel,
2011) remains unclear. In 2011, the CONTAM Panel noted that these effects were observed primarily
at concentrations also known to inhibit protein and DNA synthesis and producing cytotoxicity (EFSA
CONTAM Panel, 2011).
9.4. Anorexia and vomiting
The mechanism by which T2 and HT2 induce anorexia/emesis is not yet fully understood. Two
major mediators of anorexia/emesis, i.e. proinﬂammatory cytokines and satiety hormones, have been
proposed. Of note, contrary to humans or mink, emesis cannot occur in rodents, but the abnormal
food intake behaviour observed in mice is considered indicative of nausea-induced anorexia
(Yamamoto et al., 2002).
T2 upregulates mRNA levels of IL-1 beta, IL-6 and tumour necrosis factor (TNF)-alpha in rodents
(Agrawal et al., 2012; Gaige et al., 2014). Upon injection, the these proinﬂammatory cytokines induce
a set of symptoms characteristic of sickness behaviour, including anorexia (Kelley et al., 2003). It is
therefore possible that anorexia induction by T2 is mediated in part by sickness responses to these
cytokines (Gaige et al., 2014).
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In a study performed in mink, elicitation of emesis by T2 and HT2 corresponded to elevated plasma
concentrations of PYY3-36 and 5-HT (Wu et al., 2016), two hormones known to be involved in emesis
(Wu et al., 2013a; Lebrun et al., 2015). Similar effects were seen with DON, another trichothecene. In
experiments performed with DON, pharmacological antagonism of neuropeptide Y2 receptor, which is
activated by PYY3-36, suppressed DON-induced emesis in mink (Wu et al., 2013a). Similarly, blocking
the 5-HT3 receptor with granisetron completely inhibited induction of vomiting by DON. PYY3-36 alone
induces emesis that could be partially blocked with granisetron,6 thus indicating a possible upstream
role for PYY3-36 in 5-HT release. Therefore, both PYY3-36 and 5-HT appear to contribute to emesis
induction by DON (Wu et al., 2013a, 2016).
10. Structure–activity relationships for T2 and HT2 and their phase I
and phase II metabolites
In contrast to the chemical structures of the numerous phase I metabolites of T2 and HT2, which
have been well elucidated (see Section 7.3), only little information is available on the toxicological
activity of these metabolites. Most of the studies on structure–activity relationships (SARs) of T2
metabolites have utilised various cell systems in vitro, and only very few in vivo studies have been
conducted. Most of these SAR studies on T2 and its metabolites together with other trichothecenes
have recently been reviewed by Wu et al. (2013b).
From the toxicological data of the phase I metabolites, none of them appears to exceed the
potency of the parent toxin T2, unlike in the case of zearalenone, a mycotoxin that can be
biotransformed to a metabolite of much higher oestrogenic potency (zearalenol) than its parent
compound (EFSA CONTAM Panel, 2016).
As shown in Figure 2, the phase I metabolism of T2 essentially comprises three pathways,
viz. stepwise hydrolysis of the three ester groups (pathway A), hydroxylation (pathway B) and
de-epoxidation (pathway C). In most metabolic in vivo and in vitro studies, the hydrolytic metabolites
have been found to predominate.
10.1. Hydrolytic metabolites
The ﬁrst hydrolysis of T2 leads preferentially to HT2. The toxic potencies of T2 and HT2 have been
compared in several in vivo and numerous in vitro studies. As discussed in Section 8.1.2, HT2 is
equipotent to T2 with respect to anorectic activity in mice and emetic activity in minks. The LD50 of
HT2 in mice and broiler chicks is only slightly higher than the LD50 of T2 (Table 4). HT2 exhibited the
same lethality as T2 when administered to the midbrain of rats (Bergmann et al., 1988). A marginally
lower toxic activity of HT2 in comparison with T2 is suggested in many in vitro toxicity studies
(Table 5), with relative molar toxicity mostly between 0.2 and 0.9.
The alternative product of the ﬁrst hydrolysis of T2 is NEO (Figure 3). The LD50 of NEO is about
three and ﬁve times higher than that of T2 in mice and broiler chicks, respectively (Table 4), and the
relative molar toxicity in cellular assays ranges from 0.03 to 0.4 (Table 5).
The further hydrolysis of HT2 gives rise to T2-triol (Figure 3). In mice and broiler chicks, the LD50
of T2-triol is about 20 and six times higher than that of T2, respectively (Table 4), whereas its cerebral
toxicity in rats was about the same as that of T2 (Bergmann et al., 1988). The relative moral toxicity
of T2-triol in cellular assays ranges from 0.01 to 0.1 (Table 5).
The ﬁnal hydrolysis of the third ester group eventually leads to T2-tetraol (Figure 3). In broiler
chicks (Table 4) and in rat brain (Bergmann et al., 1988), T2-tetraol was the least toxic of the
hydrolysis products of T2. Its relative molar toxicity in most cellular assays was invariably below 0.07
and in most cases even below 0.01.
In conclusion, each consecutive cleavage of an ester group of T2 appears to reduce toxicity. This
decrease is marginal for HT2 but pronounced for T2-tetraol.
10.2. Hydroxylated metabolites
Hydroxylation of T2 and HT2 can occur at various positions, but C-19 (located in the isovaleroyl group)
appears to be preferred (see Section 7.3.1). The few studies available, e.g. induction of apoptosis in mice
(Table 4) and studies in primary human lymphocytes and baby hamster kidney cells (Table 5) imply that
19-hydroxylation of T2 does not reduce toxicity, whereas 19-hydroxylation of HT2 does.
6 A 5-HT3 receptor antagonist used as antiemetic.
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10.3. De-epoxidised metabolites
De-epoxidation of T2 and HT2 is believed to be primarily mediated by bacteria of the intestine and
rumen (see Section 7.3.1). From the only study available, i.e. in the brine shrimp assay (Table 5), the
de-epoxidation of HT2, T2-triol and T2-tetraol leads to a marked reduction in cytotoxicity. This ﬁnding
is in agreement with observations made with other 12,13-epoxytrichothecenes, e.g. deoxynivalenol
and nivalenol, for which de-epoxidation has been clearly established as a metabolic detoxiﬁcation
pathway (Wu et al., 2013b).
10.4. Hypothetical metabolites
Various compounds, which may be generated in the metabolism of T2 according to expected
pathways but have not been detected as naturally occurring metabolites to date, have been chemically
synthesised and tested for their toxicity in vitro. Most of these hypothetical T2 metabolites are acetyl
derivatives of T2 and its hydrolytic metabolites. Although the relative molar toxicities of most of these
compounds are rather low (Table 5), there are not sufﬁcient data or too much variabilities (e.g. from
0.4 to 0.01 for acetyl-T2) to derive conclusions on SARs.
10.5. Conjugated metabolites
No studies have yet been conducted on the toxicity of the conjugates of T2 and HT2 with
glucose, sulfate or glucuronic acid, formed as phase II metabolites in fungi, plants and mammals
(see Sections 4.2 and 6). Studies with other bioactive compounds, e.g. phytochemicals, have shown
that this type of phase II metabolites is, in general, devoid of biological activity per se. However,
glucosides, sulfates and glucuronides may release the aglycone after ingestion due to enzymatic
cleavage of the conjugated metabolite in the gastrointestinal tract.
10.6. Concluding remarks
Based on the limited data available, it is concluded that stepwise hydrolysis of the three ester
groups of T2 leads to a concomitant decrease in toxic activity, while hydroxylation has little effect on
toxicity. In addition to ester hydrolysis, de-epoxidation constitutes a detoxifying metabolic pathway.
Ester hydrolysis and de-epoxidation are irreversible metabolic reactions. In contrast, formation of
phase II metabolites through conjugation with glucose, sulfate or glucuronic acid, although
presumably abolishing toxicity, is reversible and might release the aglycone upon ingestion.
11. Dose–response analysis
11.1. Acute effects
There are new studies reporting anorectic effects (e.g. feed refusal, retching, vomiting, reduced
body weight gain) at low doses in several species (mouse, mink and pig). Therefore, the study of Wu
et al. (2016) in mink, in which acute effects were observed at the lowest dose, was used by the
CONTAM Panel as a basis for BMD analysis of acute effects of T2 and HT2. Following oral gavage in
two independent tests, one with T2 and one with HT2, each with four animals/dose groups, identical
results at identical doses were seen. Notably, the emetic events were associated with elevated plasma
concentrations of PYY3-36 and 5-HT (Wu et al., 2016), two hormones known to be involved in emetic
effects (Wu et al., 2013b; Lebrun et al., 2015).
Using a benchmark response (BMR) of 10% resulted in a benchmark dose 10% (BMD10) total
conﬁdence interval (BMDL10–BMDU10) of 2.97–49.8 lg T2 or HT2/kg bw per day across the applied
models. The two independent tests, were combined to increase the statistical power of the BMD
modelling (details on the calculations are provided in Appendix D). Due to the large dose spacing at the
lower doses and the small number of animals used (low statistical power), the CONTAM Panel considers
the BMDL10 as a conservative estimate (BMDL10 is below the lowest dose tested, 5 lg T2 or HT2/kg bw,
and showing no effect). The CONTAM Panel used this value of 2.97 lg T2 or HT2/kg bw as a reference
point for characterising the acute toxicity of T2 and HT2.
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11.2. Chronic effects
Since the EFSA evaluation (EFSA CONTAM Panel, 2011), there has been no new evidence that other
toxic effects including dermal toxicity, developmental and reproductive toxicity and neurotoxicity occur
at doses lower than those causing immunotoxicity and haematotoxicity in pigs.
In its 2011 evaluation, EFSA noted that there was substantial evidence for the immunotoxicity and
haematotoxicity of T2 in several species (EFSA CONTAM Panel, 2011). In 2011, EFSA identiﬁed a
LOAEL of 0.029 mg/kg bw per day in a short-term study with pigs (Rafai et al., 1995). Based on a
BMD analysis of the decrease in anti-horse globulin titre values, a 95% lower conﬁdence limit for the
benchmark dose response of 5% (BMDL05) of 10 lg T2/kg bw per day was calculated.
Since 2011, several subacute and subchronic toxicity studies have been published. In the 90-day
study in rats by Rahman et al. (2014), dose-dependent decreases in total erythrocyte, leucocyte and
thrombocyte counts as well as a decrease in the percentage of lymphocytes were observed. This study
has been performed with T2 obtained from cultures of F. sporotrichioides var. sporotrichioides
MTCC 1894. Data obtained by Rahman et al. (2014) are in accordance with haematotoxicity described
for several other species, i.e. mice, pigs, humans and monkeys, in the previous EFSA assessments
(EFSA CONTAM Panel, 2011). In the Rahman et al. (2014) study, the duration of exposure of animals
(rats) to T2 is longer (90 days) in absolute terms, but also relative to species life time than in the Rafai
et al. (1995) study, in pigs (21 days). Furthermore, it is noted that the toxic effect in the study of
Rahman et al. (2014) progressed during the whole study period with no signs of reaching a plateau at
the end.
In a similar 90-day study (Raut et al., 2013), a strong decrease in total thrombocytes count and less
decreases in erythrocyte and leucocyte counts were observed. It is noted that in the Rafai et al. (1995)
study in addition to decreased leucocyte counts functional endpoints such as reduced anti-horse
globulin titre formation were observed at the lowest dose tested, 29 lg T2/kg bw per day. However, the
Scientiﬁc Committee on Food (2001) based its assessment on a similar LOAEL for several immune
parameters including a decrease in total leucocytes, EFSA (EFSA CONTAM Panel, 2011) used reduced
anti-horse globulin titre formation as basis for establishing a HBGV.
For the present assessment, the CONTAM Panel performed BMD analyses of several haematotoxic,
immunotoxic as well as other endpoints in the studies by Rafai et al. (1995) and Rahman et al. (2014).
These endpoints were: (i) total leucocyte count in the Rafai et al. (1995) study and (ii) total leucocyte
count, total erythrocyte count, total thrombocyte count, haemoglobin (Hb) concentration and body
weight in the Rahman et al. (2014) study. The Panel noted that, in essence, the effects observed
(i.e. anorectic effects and effects on immune system and blood parameters) in the new (longer term)
rat study were essentially similar to those seen in the pig study conﬁrming the immune system and the
blood cell production as target organs of T2 through species.
Therefore, the CONTAM Panel decided, considering the longer exposure duration of the study from
Rahman et al. (2014) and its biological relevance, to use the total leucocytes count reported from this
study for calculating a new BMD for T2 (for details on BMD calculations, see Appendix E). The
CONTAM Panel used a BMR of 10% was used considering such a response in leucocyte counts to be
within the individual physiological variation and negligible, and further noted that the selected BMR is
slightly below the control standard deviation of the controls in the Rahman et al. study (14%). A 95%
lower conﬁdence limit for the benchmark dose response (BMDL10) of 3.3 lg T2/kg bw was derived.
The CONTAM Panel used this value as a reference point for establishing a chronic HBGV for T2 and
HT2. Additional BMD calculations have been carried out with several other potentially relevant
endpoints (next to total leucocyte count in the Rahman et al. (2014) study) measured in the studies
described above to gauge their appropriateness to derive a TDI. These alternative calculations are
provided as supporting information to the present opinion.
12. Establishment of health based guidance values
12.1. Establishment of a group acute reference dose (ARfD) for T2 and
HT2 and their modiﬁed forms
The CONTAM Panel decided to use the BMDL10 of 2.97 lg T2 or HT2/kg bw derived for emetic
response in mink as a reference point for establishing a group ARfD for T2 and HT2. An UF of 10 for
intraspecies variability was applied. No interspecies variability factor was applied because humans were
not considered more sensitive than mink to the acute emetic effect of T2 or HT2, an assumption
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supported by studies on emesis with emetine showing that similar doses of the compound are
effective both in humans and mink (Gordon, 1985; Zhang et al., 2006; Percie du Sert et al., 2012). An
ARfD of 0.3 lg (rounded from 0.297 lg) T2 or HT2/kg bw was established.
With regard to phase I metabolites, NEO was equipotent with T2 and HT2 when tested for
vomiting in ducklings (Ueno et al., 1974; see Table 4). Therefore, the CONTAM Panel decided that NEO
can be included with a relative potency factor (RPF) of 1 (i.e. a molarity based potency factor relative
to T2) together with T2 and HT2 in a group ARfD.
None of the other phase I metabolites have been tested with regard to emetic response. The data
on comparative toxicity of T2 and HT2 with its metabolites presented in Section 8 cannot be related to
emesis and therefore not be used to assess relative emetic potency of metabolites. Consequently, due
to the lack of appropriate data, other phase I metabolites cannot be included in a group ARfD.
Since phase II metabolites of T2, HT2 and NEO are assumed to be hydrolysed to their parent
compounds (aglycones) after ingestion, they are included in a group ARfD with the same potency as
their parent compounds.
12.2. Establishment of group tolerable daily intake (TDI) for T2 and HT2
and their modiﬁed forms
The CONTAM Panel decided to use the BMDL10 of 3.3 lg T2/kg bw per day derived for reduction in
the number of peripheral leucocytes in a subchronic study in rats as a basis for establishing a TDI for
T2. An UF of 200 was used taking into account 10 for interspecies, 10 for intraspecies variability and
two for extrapolation from subchronic to chronic exposure duration (see EFSA Scientiﬁc Committee,
2012) and for the fact that the toxic effect progressed during the whole study period with no signs of
reaching a plateau at the end of the study. A TDI of 0.02 (rounded from 0.0165) lg T2/kg bw per day
was established.
Haematotoxicity with reduced production of erythrocytes, leucocytes and platelets, is the critical
chronic effect of T2. The underlying mode of action is inhibition of protein synthesis, induction of
ribotoxic stress and apoptosis. Based on similar toxic proﬁle and potency, structural similarity and the
fact that HT2 is an immediate metabolite of T2 in agreement with the EFSA assessment of 2011, it
was concluded that T2 and HT2 can be included in a group TDI with the same potency.
No in vivo studies on haematotoxicity of modiﬁed forms of T2 and HT2 have been identiﬁed. It is,
however, assumed that phase I metabolites work via a similar mode of action as some have been
shown to cause protein synthesis inhibition, and may as such induce haematotoxicity. The CONTAM
Panel therefore considered it appropriate to include modiﬁed forms in a group TDI assuming dose
addition as a model of joint action. Because the potencies of phase I metabolites differ with respect to
the inhibition of protein synthesis and other toxic effects, it was decided to assign RPFs on a molar
basis.
12.3. Assignment of relative potency factors for chronic effects
When assigning different potency factors to the phase I metabolites of T2 and HT2, in vivo and
in vitro studies on comparative toxicity in vivo and in vitro (see Tables 4 and 5) were used. The
CONTAM Panel noted that none of the phase I metabolites examined were more potent than T2 of
HT2. Since in vitro cell systems (presented in Table 5) may have a limited capacity for detoxiﬁcation,
results would in general overestimate toxicity of T2 because as compared to the in vivo situation.
Therefore, in vivo data are preferentially used. When there are different values of relative potencies for
one metabolite, the highest potency was selected to avoid underestimation of relative toxicity. Only
metabolites that have been examined either in vivo or in vitro have been considered for establishing
relative potencies as listed in Table 6. Since phase II metabolites are assumed to be hydrolysed to
their parent compounds (aglycons) after ingestion, they should be included in a group TDI with the
same potency as their parent compounds. The (RPFs have been calculated for each study on a molar
basis (see Tables 4 and 5). They have been rounded up to half orders of magnitude, i.e. 1, 0.3 or 0.1
to avoid spurious accuracy but retaining a conservative approach.
According to information on SAR as described in Section 10.3, deperoxidation generally leads to a
marked reduction in toxicity, which is in agreement with the effect of deperoxidation of other
trichothecenes (Wu et al., 2013a). Deperoxidised metabolites where therefore not considered for
inclusion in a group TDI.
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In Appendix F, an example calculation on how the factors can be applied in practice for inclusion of
modiﬁed forms of T2 and HT2 for a chronic risk assessment is provided.
13. Uncertainties
The CONTAM Panel identiﬁed a series of uncertainties in their evaluation of the appropriateness to
set a group HBGVs for T2 and HT2 and its modiﬁed forms.
Upon reviewing new data, the TDI set for T2 in 2011 (EFSA CONTAM Panel, 2011) has been
revised using a reduction in total leucocyte counts in a 90-day rat study with T2 as a critical endpoint
for establishing a chronic BMD10. The test compound was puriﬁed from fungal culture material and its
ﬁnal purity was not speciﬁed. It can therefore not be excluded that minor amounts of other
mycotoxins including modiﬁed forms were present in the test material. Using a subchronic study for
setting, a chronic HBGV is also associated with considerable uncertainty. Although no repeated dose
studies are available on HT2, this toxin has been included in a group TDI with T2 based on similar
toxic proﬁle and potency, structural similarity and the fact that HT2 is an immediate metabolite of T2.
No subchronic toxicity data on total leucocyte counts with any of the T2 and HT2 phase I
metabolites were available. The CONTAM Panel decided to include all phase I metabolites, for which
either in vivo or in vitro studies comparing their acute toxicity to that of T2 or HT2 were available, in a
group TDI together with T2 and HT2. The highest effective molar doses/concentrations of these
metabolites relative to those of T2 were used to derive RPFs, which were then rounded up to half an
order of magnitude of either 1, 0.3 or 0.1 to avoid spurious accuracy. Application of RPFs for chronic
risk assessment on basis of results from acute studies was done assuming the same underlying mode
of action, binding to ribosomes with inhibition of protein synthesis and ribotoxic stress, for both acute
effects (other than emetic effects) and chronic effects. The Panel noted that the derivation of RPFs for
the different phase I metabolites from acute toxicity studies for including phase I metabolites of T2
and HT2 is associated with a very signiﬁcant uncertainty, probably overestimating the relative toxicity.
Table 6: Relative potency factors (RPFs) for chronic effects of modiﬁed forms of T2
Compound
Relative potency
factor (RPF)(a)
Reference
T2 1 n.a.
T2-3-Glc 1 Hydrolysation to T2 assumed
T2-3-diGlc 1 Hydrolysation to T2 assumed
T2-3-Sulf 1 Hydrolysation to T2 assumed
T2-3-GlcA 1 Hydrolysation to T2 assumed
3-Ac-T2 1 Hydrolysation to T2 assumed
3-Fer-T2 1 Hydrolysation to T2 assumed
19-HO-T2 1 See Tables 4 and 5, Section 8
HT2 1 See Tables 4 and 5, Section 8
HT2-3-Glc 1 Hydrolysation to HT2 assumed
HT2-diGlc 1 Hydrolysation to HT2 assumed
HT2-GlcA 1 Hydrolysation to HT2 assumed
HT2-MalGlc 1 Hydrolysation to HT2 assumed
19-HO-HT2 0.3 See Tables 4 and 5, Section 8
NEO 0.3 See Tables 4 and 5, Section 8
NEO-Glc 0.3 Hydrolysation to NEO assumed
T2-triol 0.1 See Tables 4 and 5, section 8
T2-triol-Glc 0.1 Hydrolysation to T2-triol assumed
T2-tetraol 0.1 See Tables 4 and 5, Section 8
T2-tetraol-Glc 0.1 Hydrolysation to T2-tetraol assumed
n.a.: not applicable ; Glc: glucoside; diGlc: diglucose; Sulf: sulfate; GlcA: glucuronic acid; Ac: acetyl; Fer: feruloyl; MalGlc:
malonylglucose; NEO: neosolaniol.
(a): RPFs have been rounded up to half an order of magnitude, i.e. to either 1, 0.3 or 0.1.
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An ARfD for T2 and HT2 has been established based on a BMDL10 derived from observations of
emesis in two similar acute studies with T2 and HT2. The large dose spacing at the lower doses in
these studies and the small number of animals used lead to a BMDL10 calculation associated with
considerable uncertainty.
NEO was included with the same RPF in a group ARfD with T2 and HT2 on the basis of a single
in vivo study where emetic effects have been observed at the same dose for the three compounds.
In the absence of data on phase II metabolites (conjugates) of T2 and HT2 and their phase I
metabolites, the CONTAM Panel assumed these release of their aglycones upon ingestion and that
therefore phase II metabolites should be included in the group HBGVs and RPFs for their parent
compounds be applied.
Dose additivity of T2 and HT2 and their modiﬁed forms is assumed, although antagonistic or less
likely synergistic effects of their co-occurrence cannot be excluded in principle.
There is a lack of analytical standards for detection of modiﬁed forms of T2 and HT2. Analytical
detection of modiﬁed forms of T2 and HT2 are often based on semi- or relative quantiﬁcation.
13.1. Summary of uncertainties
In Table 7, a summary of the uncertainty evaluation is presented, highlighting the main sources of
uncertainty and indicating an estimate of whether the source of uncertainty leads to over/
underestimation of the resulting risk.
The overall uncertainty associated with the inclusion of modiﬁed forms of T2 and HT2 into a group
ARfD and a group TDI in the present assessment is considered as high and it would rather
overestimate than underestimate any risk.
14. Conclusions
14.1. Introduction
T2 and HT2 are members of the type A group trichothecenes, which are tetracyclic
sesquiterpenoids produced by many Fusarium species infesting crop plants. In addition to T2 and HT2,
produced by Fusarium species, plants, fungi and mammals generate a large number of modiﬁed forms
by phase I and phase II metabolism. Reliable analytical methods (based mainly on LC–MS/MS) for T2,
HT2 and their phase II metabolites are available. Due to a lack of commercially available standards
and reference materials, validated methods to quantify phase I metabolites are not available.
14.2. Occurrence of modiﬁed forms of T2 and HT2
• There are few data on occurrence of modiﬁed forms of T2 and HT2, mainly conjugates, with
grain products being their main source. The proportion of their occurrence relative to the
respective parent compounds, in the few samples where this has been determined, varies
widely. Recent reports show the frequent occurrence of conjugates, in particular glucosides, of
T2 and HT2 even in samples were their parent compounds are not detected.
• There are no data available on the occurrence of modiﬁed forms of T2 and HT2 in food from
animal origin.
Table 7: Summary of the qualitative evaluation of the impact of uncertainties on the assessment
Sources of uncertainty Direction(a)
Purity of test compound in subchronic tests with T2 was not speciﬁed, thus it cannot be
excluded that minor amounts of other mycotoxins or modiﬁed forms were also present
+
Inclusion of modiﬁed forms of T2 and HT2 in a group TDI based on subchronic toxic effects
observed for T2
+
Use of results from acute toxicity tests for derivation of relative potency factors and inclusion
of metabolites in group TDI for chronic effects
+/
Numerical values of RPFs are rounded to up to half an order magnitude +
Assumption of complete cleavage of phase II metabolites to their parent compounds +
Assumption of dose additivity for T2 and HT2 and its modiﬁed forms +/
(a): +: uncertainty with potential to cause overestimation of exposure/risk; : uncertainty with potential to cause
underestimation of exposure/risk; +/: extent of potential over/underestimation might differ in direction.
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14.3. Toxicokinetics of T2 and HT2 and their modiﬁed forms
• Upon ingestion, T2 appears to be rapidly absorbed. It is rapidly hydrolysed to HT2 and
distributed to the liver, kidney and other organs without accumulation. No studies on absorption
or distribution of modiﬁed forms of T2 or HT2 have been identiﬁed.
• There are no data on absorption of phase I metabolites from food. They are assumed to be
easily absorbed, distributed and entering metabolism as described for T2. No data are
available on the absorption of phase II metabolites of T2 and HT2. It is assumed that such
phase II metabolites are hydrolysed in the gastrointestinal tract after ingestion, releasing their
aglycones, which can then be absorbed.
• Phase I metabolism is predominated by hydrolysis of ester groups, leading to NEO, T2-triol and
eventually T2-tetraol. Hydroxylation reactions appear to be less pronounced. Another phase I
reaction, mostly in the ruminal microﬂora, is de-epoxidation. Phase II metabolism comprises
the formation of glucuronides in mammals.
• Mammals excrete T2 and its phase I and phase II metabolites of T2 within 2–3 days in urine
and faeces.
14.4. Toxicity of T2 and HT2 and its modiﬁed forms
• In vivo acute toxicity studies (supported by subacute studies) show that T2 and HT2 have
anorectic effects upon short-term exposure. Emetic events observed upon single oral and i.p.
exposures to both T2 and HT2 in mink were identiﬁed as the critical acute effects.
• Only a few in vivo studies have been identiﬁed in which the acute toxicity of phase I
metabolites of T2 and HT2 was compared with T2 and HT2. Effects investigated were lethality,
induction of apoptosis and emesis. It was shown that the toxic potencies of the metabolites
tested were either equal or less than that of T2 or HT2.
• In vivo subacute and new subchronic tests show that T2 causes haematotoxicity (and
myelotoxicity). Reduction in total leucocyte counts seen in a 90-day rat study was identiﬁed as
the critical chronic effect of T2.
• No subacute, subchronic or chronic studies comparing the toxicity of T2 and HT2 to their
modiﬁed forms have been identiﬁed. In the absence of repeated dose studies on HT2, it is
assumed that HT2 exerts similar toxicity as T2. This is based on structural considerations and
on the rapid metabolism of T2 to HT2.
• A series of in vitro studies on toxicity of T2 and HT2 in comparison to its phase I metabolites
have been identiﬁed, the endpoints being mainly inhibition of protein synthesis or cell viability.
In vitro toxicity was always highest for T2. HT2 was almost as active as T2, whereas NEO and
T2-triol and 19-OH-HT2 were less active. T2-tetraol invariably exhibited the lowest toxicity.
• No relevant information has been identiﬁed on the toxicity of phase II metabolites of T2 and
HT2 and their phase I metabolites.
14.5. Mode of action for toxicity
• T2 interferes with the peptide bond formation and is a protein synthesis inhibitor and induces
ribotoxic stress. It inhibits DNA and RNA synthesis but at concentrations higher than those
inhibiting protein synthesis. T2 induces lipid peroxidation by generating free radicals. Rapidly
proliferating tissues such as haematopoietic tissue are targets of T2. T2 induces apoptosis
which can lead to leucopoenia and thrombocytopenia but the exact mechanism of induction is
not fully understood.
• Elicitation of emesis by T2 and HT2 in mink is mediated by systemic effects involving, i.e. the
PYY3-36) and 5-HT. In rodents, emesis cannot occur, but the abnormal anorectic effect
observed in mice following T2 and HT2 exposure is considered indicative of systemic induction
of nausea by similar mechanisms.
• No information on mode of action of toxicity of modiﬁed forms of T2 or HT2 were identiﬁed.
14.6. Structure–activity relationships
• Stepwise hydrolysis of the three ester groups of T2 leads to a concomitant decrease in toxic
activity, while hydroxylation has little effect on toxicity. De-epoxidation constitutes a detoxifying
metabolic pathway.
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• Formation of phase II metabolites through conjugation with glucose, sulfate or glucuronic acid,
although presumably abolishing toxicity, is reversible and might release the aglycone upon
ingestion.
14.7. Acute and chronic dose–response analysis
• The CONTAM Panel selected the emetic effects of T2 and HT2 for the acute hazard
characterisation. A BMD analysis was performed on a combined data set on the incidence of
emetic events in mink exposed to either T2 or HT2.
• The BMD modelling using a BMR of 10% resulted in a benchmark dose 95% lower and upper
conﬁdence interval (BMDL10–BMDU10) of 2.97–49.8 lg T2 or HT2/kg bw across the applied
BMD models.
• For chronic toxicity, the CONTAM Panel selected the decrease in total leucocyte count observed
in a subchronic study on T2 in male Wistar rats as the critical effect. For this BMD analysis, the
CONTAM Panel selected a BMR of 10%. A 95% BMDL10–BMDU10 conﬁdence interval of
3.33–27.6 T2/kg bw per day across the applied models was calculated.
14.8. Group acute reference dose for T2 and HT2 and their modiﬁed
forms
• Based on new studies reporting anorectic effects (e.g. feed refusal, retching, vomiting,
reduced body weight gain), the CONTAM Panel established a group ARfD for T2 and HT2 using
a BMDL10 of 2.97 lg/kg bw for T2 and HT2 based on their emetic effects. Using an UF of 10,
for intraspecies differences and an ARfD of 0.3 (rounded from 0.297) lg T2 or HT2/kg bw was
established. An interspecies UF was not included because humans were not considered more
sensitive to this endpoint than the mink.
• NEO, a phase I metabolite showing emetic effects at a similar dose (at molar basis) as T2 and
HT2, was included in the group ARfD with the same potency factor (i.e. 1).
• In the absence of data on emetic effects of phase II metabolites, it is assumed that these will
be hydrolysed in the intestine with the release of T2 or HT2 or their phase I metabolites.
Therefore, the Panel found it appropriate to include these phase II metabolites with the same
potency factor (i.e. 1, expressed on a molar basis) in the group ARfD.
14.9. Group tolerable daily intake for T2 an HT2 and their modiﬁed
forms
• The CONTAM Panel used a new 90-day study in rats and decreases in leucocyte counts as the
critical endpoint and derived a BMDL10 of 3.3 lg T2/kg bw. Based on rapid metabolism of T2
to HT2 and structural similarities, this value was used as a reference point for establishing a
TDI for T2 or HT2. An UF of 200 was used taking into account 10 for interspecies and 10 for
intraspecies variation and a factor of 2 since it was a subchronic study. A TDI of 0.02 (rounded
from 0.017 lg T2 or HT2/kg bw) was established.
• Haematotoxicity with reduced production of erythrocytes, leucocytes and platelets is the critical
effect of T2. It is assumed that phase I metabolites exert toxicity via a similar mode of action,
and therefore, the CONTAM Panel considered it appropriate on the assumption of dose
addition, to include the modiﬁed forms NEO, T2-triol and T2-tetraol in a group TDI.
• It was decided, to assign RPFs on a molar basis because of different potencies of phase I
metabolites in inhibition of protein synthesis and other toxic effects. These are 1 for T2, HT2
and 19-HO-T2, 0.3 for NEO and 19-HO-HT2 and 0.1 for T2-triol and T2-tetraol.
• Phase II metabolites of T2, HT2, NEO, T2-triol and T2-tetraol can be hydrolysed to their
parent compounds after ingestion. They can be included in the Group TDI and be applied the
same RPF. Thus, T2-3-Glc, T2-3-diGlc, T2-3-Sulf, T2-3-GlcA, HT2-3-Glc, HT2-diGlc, HT2-GlcA,
HT2-MalGlc can be included by applying an RPF of 1. NEO-Glc and can be included using a
factor 0.3 and T2 triol-Glc and T2-tetraol-Glc by applying a factor of 0.1.
15. Recommendations
• The chemical structures of the phase I and phase II metabolites of T2 and HT2, which have
not been fully characterised, should be established.
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• Certiﬁed reference materials and standards for the modiﬁed forms of T2 and HT2 are needed.
• More information on the occurrence of modiﬁed forms with appropriate standards of T2 and
HT2 in feed and food is needed.
• Studies on the toxicokinetics of modiﬁed forms of T2 and HT2, in particular major conjugates
(glucosides) occurring in plant-derived food items, should be conducted.
• More data on toxicity are needed, in particular on emetic effects and on haematopoiesis of
modiﬁed forms of T2/HT2 with appropriate study design and speciﬁed purity of the compounds
applied.
• Testing the dose additivity assumption is needed.
• Comparative toxicity data on T2 and HT2 and their modiﬁed forms are needed.
Addendum
After adoption of this opinion, a study providing further information on the formation of modiﬁed
forms of T2 and HT2 in cereals was published. Eight additional metabolites were described: One phase
I metabolite, i.e. hydroxy-HT2, and seven phase II metabolites, i.e. two isomers of hydroxy-HT2-diGlc,
hydroxy-HT2-anhydro-diGlc, HT2-MalGlc, HT2-anhydro-diGlc, 15-acetyl-18,19-dehydro-T2-tetraol-Glc
and 18,19-dehydro-HT2-Glc.
Meng-Reiterer J, Bueschl C, Rechthaler J, Berthiller F, Lemmens M and Schuhmacher R, 2016.
Metabolism of HT-2 toxin and T-2 toxin in oats. Toxins, 8, 364–385, doi:10.3390/toxins8120364
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Abbreviations
5-HT 5-hydroxytryptamine
Ac acetyl
AIC Akaike’s information criterion
ALP alkaline phosphatase
ALT alanine amino transferase
ARfD acute reference dose
AST aspartate amino transferase
BMD benchmark dose
BMD10 the benchmark response of 10% resulted in a benchmark dose 10%
BMDL5 the 95th benchmark dose lower conﬁdence limit
BMDL10 the 90th benchmark dose lower conﬁdence limit
BMDU5 the 95th benchmark dose upper conﬁdence limit
BMDU10 the 95th benchmark dose upper conﬁdence limit
BMR benchmark response
BeWo cells human placental choriocarcinoma cells
bw body weight
CAS Chemical Abstracts Service
CD cluster of differentiation
ConA concanavalin A
CONTAM Panel EFSA Panel on Contaminants in the Food Chain
CYP cytochrome P450
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DART-MS direct-analysis-in-real-time mass spectrometry
DE deoxy, de-epoxy
diGlc diglucose
DON deoxynivalenol
EC50 half maximal effective concentration
ED50 median effective dose
ERK extracellular signal-regulated kinase
FAO Food and Agriculture Organization of the United Nations
Fer feruloyl
GC gas chromatography
GD gestation day
Glc glucoside, glucose
GlcA glucuronic acid
Hb haemoglobin
HBGV health based guidance value
HO hydroxyl
HPLC high-performance liquid chromatography
HPLC-FLD high-performance liquid chromatography–ﬂuorescence detection
HPLC–MS/MS high-performance liquid chromatography–tandem mass spectrometry
Hsp90 heat shock protein 90
HT2 HT2-toxin
IFN interferon
IL interleukin
i.p. intraperitoneal
i.v. intravenous
IUPAC International Union of Pure and Applied Chemistry
JNK c-Jun N-terminal kinase
KBD Kashin–Beck disease
LC liquid chromatography/left-censored
LC-FLD liquid chromatography-ﬂuorescence detection
LC–HRMS liquid chromatography–high-resolution mass spectrometry
LC–MS/MS liquid chromatography–tandem mass spectrometry
LD50 median lethal dose
LOAEL lowest-observed-adverse-effect-level
LPO lipid peroxidase
Mal malonyl
MalGlc malonylglucose
Man mannose
MAPK mitogen-activated protein kinase
MCV mean corpuscular volume
MDA malondialdehyde
ML maximum level
m.p. melting point
mRNA messenger RNA
MS mass spectrometry, mass spectrum
MS/MS tandem mass spectrometry
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MW molecular weight
NEO neosolaniol
NMR nuclear magnetic resonance
NOAEL no-observed-adverse-effect-level
QuEChERS Quick, easy, cheap, effective, rugged and safe
PND post-natal day
p.o. Per os
PYY-36 pancreatic peptide YY3-36
RNA ribonucleic acid
ROS reactive oxygen species
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RPF relative potency factor
SAPK stress activated protein kinase
SAR structure–activity relationship
s.c. subcutaneous
SCF Scientiﬁc Committee on Food
SE standard error
SOD superoxide dismutase
Sulf sulfate
T2 T2-toxin
TDI tolerable daily intake
TNF tumour necrosis factor
UDP uridine 50-diphosphate
UDPGA uridine 50-diphosphate glucuronic acid
UF uncertainty factor
UGT UDP glucosyltransferase
WHO World Health Organization
Xyl xylose
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Appendix A – Search for scientiﬁc literature on T2 and HT2 toxin and their
modiﬁed forms
Table A.1: Search terms and information source for literature search on T2 and HT2 and their
modiﬁed forms
EFSA Systematic Review
Chemistry and analysis
Search terms TOPIC: (T2-toxin OR HT-2 toxin) AND TOPIC: (chemistry OR analysis OR determination
OR detection OR identiﬁcation OR formation OR GC OR GC-MS OR HPLC OR LC-MS OR
ICP-MS)
Information source Number of records retrieved
Web of Science 705
PubMed 268
Metabolism, Kinetics
Search terms TOPIC: (T2-toxin OR HT-2 toxin) AND TOPIC (toxicokinetic* OR metabolism OR
distribution OR excretion OR absorption OR distribution OR biomarker OR mode of
action OR biotransformation OR elimination OR reduction OR detoxiﬁcation OR
extraction)
Information source Number of records retrieved
Web of Science 471
PubMed 213
Toxicity
Search terms TOPIC: (T2-toxin OR HT-2 toxin) AND TOPIC: (toxicity OR toxic* OR acute OR subacute
OR subchronic OR chronic OR mutagen* OR carcino* OR genotox* OR reprotox* OR
nephrotox* OR neurotox* OR hepatotox* OR immunotox* OR haemotox* OR
hematotox* OR hemotox OR cytotox* OR develop* toxicity OR thyroid OR endocri* OR
poisoning OR incidental poisoning OR rat OR mouse OR lab animal OR animal*)
Information source Number of records retrieved
Web of Science 966
PubMed 202
Human data
Search terms TOPIC: (T2-toxin OR HT-2 toxin) AND TOPIC: (biomarker OR biological marker OR
case study OR incidental poisoning OR poisoning OR human poisoning OR human
OR epidemiol*)
Information source Number of records retrieved
Web of Science 586
PubMed 231
Date accessed January 2016
Total number
retrieved
3,542
Total number after
duplicates removed
1,087
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Appendix B – Chemical structures of T2 and HT2 and their phase I
metabolites
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Appendix C – Chemical structures of phase II metabolites of T2 and HT2
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Appendix D – Derivation of a BMD for acute effects of T2 and HT2
The dose-dependent incidences of emesis upon administration of T2 and HT2 in mink in the study
from Wu et al. (2015) has been selected for derivation of a BMD for T2 and HT2 by applying expert
knowledge and following the new EFSA guidance on the use of the BMD (EFSA Scientiﬁc Committee,
2017). The ﬁndings selected for deriving a BMD are described extensively in Sections 8, 11 and 13 of
this opinion.
D.1. Data
Substance
Dose
(lg/kg bw)
Animals showing
emesis
N Sex
T2 0 0 4 F
5 0 4 F
50 3 4 F
250 4 4 F
500 4 4 F
HT2 0 0 4 F
5 0 4 F
50 3 4 F
250 4 4 F
500 4 4 F
bw: body weight.
N: number of animals.
D.2. BMR: 10% (extra risk)
D.3. Software used: Proast v38.9
D.4. Additional assumptions
The results from two independent experiments on T2 and HT2 were combined considering the
experiments as covariate.
D.5. Table of results
Models
No of
parameters
Log
likelihood
AIC(a)
BMDL10
(lg/kg bw)(b)
BMD10
(lg/kg bw)(b)
BMDU10
(lg/kg bw)(b)
Full 8 4.50(e) 25.00 – – –
Null 2 27.73 59.05 – – –
Gamma 3 4.50 15.00 2.97 28.3 44.3
Logistic 2 4.50 13.00 12.30 42.7 49.8
LogLogistic 3 4.50 15.00 4.29 37.1 47.1
LogProbit 3 4.50 15.00 4.02 26.8 49.7
Two-stage(c) 3 4.61 15.22(b) NR(d) NR(d) NR(d)
Probit(e) 2 4.50 13.00 11.0 36.1 NR(d)
Weibull 3 4.50 15.00 3.02 29.9 47.9
(a): AIC: Akaike’s information criterion.
(b): BMD: benchmark dose calculated at 10% extra risk. BMDL10: 95th lower conﬁdence limit (one-sided) of BMD; BMDU10: 95th
upper conﬁdence limit (one-sided) of BMD.
(c): Model not fulﬁlling the criterion (AIC ≤ AICmin +2).
(d): NR: Not reported.
(e): Calculated using BMDS v2.6.086, pooling data from the two experiments.
The overall BMDL–BMDU range is 2.97–49.8 lg/kg bw (when considering all models with
AIC ≤ AICmin + 2).
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D.6. Figures of ﬁtted models
D.7. Conclusion
Following the provisions of the EFSA guidance (EFSA Scientiﬁc Committee, 2017), a BMDL10 of
2.97 lg/kg bw was selected for further consideration as this was the lowest valid BMDL10.
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Figure D.1: Dose–response curves with ﬁtted models
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Appendix E – Derivation of a BMDL for subchronic effects of T2
The dose-dependent reduction in total lymphocyte counts upon administration of T2 in rats in the
study from Rahman et al. (2014) has been selected for derivation of a BMDL for T2 for
subchronic/chronic effects by applying expert knowledge and following the new EFSA guidance on the
use of the BMD (EFSA Scientiﬁc Committee, 2017). Notably, a series of other potentially relevant effects
seen in repeat dose experiments with T2 have been used for alternative calculations of a chronic BMD.
The BMD derived as presented in this appendix is the most appropriate and has therefore been used for
risk characterisation. The calculations with alternative endpoints are presented in the Annex A to this
opinion.
E.1. Data
Dose (lg/kg bw per day)
Mean total leucocyte
count (3 103 per lL)
SE(a) N Sex
0 14.83 0.73 8 M
45 8.95 0.36 8 M
68 6.92 0.83 8 M
90 5.2 0.73 8 M
(a): SE: standard error.
E.2. BMR: 10%
A deviation from the default is appropriate both for statistical reasons (effects calculated at
BMDL05–BMDU05 would fall under the standard deviation of total leucocyte count in the control group)
and biological reasons since a 5% variation in total leucocyte counts would still fall under normal
variations for the concerned endpoint.
E.3. Software used: PROAST 38.9
E.4. Additional assumptions
None.
E.5. Tables of results
Model
No of
parameters
Log
Likelihood
AIC BMDL10 BMD10 BMDU10
Null model 1 21.99 45.98
Exponential Model 3(a) 3 1.14 8.28 3.30 11.52 23.75
Model 5 4 1.14 10.28
Hill Model 3(a) 3 1.15 8.30 5.95 15.70 27.60
Model 5 4 1.15 10.30
Full model 4 1.14 10.28
AIC: Akaike’s information criterion; BMD: benchmark dose calculated at 10% extra risk. BMDL10: 95th lower conﬁdence limit
(one-sided) of BMD; BMDU10: 95th upper conﬁdence limit (one-sided) of BMD.
(a): Model with lowest AIC.
The overall BMDL–BMDU range is 3.30–27.60 lg/kg bw (when considering all models with
AIC ≤ AIC min + 2).
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E.6. Figure of ﬁtted models
E.7. Conclusion
Following the provisions of the EFSA guidance, a BMDL10 of 3.3 lg/kg bw per day was selected for
further consideration as this was the lowest valid BMDL10.
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Figure E.1: Dose–response curves resulting from application of the Exponential and Hills models
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Appendix F – Example calculation for inclusion of modiﬁed forms of T2 and
HT2 in a chronic risk assessment
Example T2-Triol:
Assumed is a total exposure of 0.03 lg T2-triol/kg bw per day. The RPF for T2-triol is 0.3.
MW of T2 is 466. MW of T2-triol is 382. The resulting correction factor for molar weight is
466/382 = 1.22. The resulting total exposure to T2-triol expressed as T2 equivalents is
0.03 9 1.2 9 0.3 = 0.0108 lg/kg bw per day (i.e. lower than the group TDI of 0.02 lg/kg bw per day).
Correction factors for molar weight for the different modiﬁed forms of T2 and HT2 are provided in
Table F.1.
Table F.1: Molecular weights and correction factors for molar weights to be applied
Compound Molar weight
Correction factor to be applied
for differing molar weight(a)
T2 466 1.00
T2-3-Glc 628 0.74
T2-3-diGlc 790 0.59
T2-3-Sulf 546 0.85
T2-3-GlcA 642 0.73
3-Ac-T2 508 0.92
3-Fer-T2 642 0.73
19-HO-T2 482 0.97
HT2 424 1.10
HT2-3-Glc 586 0.80
HT2-diGlc 748 0.62
HT2-GlcA 600 0.78
HT2-MalGlc 672 0.69
19-HO-HT2 440 1.06
NEO 382 1.22
NEO-Glc 544 0.86
T2-triol 382 1.22
T2-triol-Glc 544 0.86
T2-tetraol 298 1.56
T2-tetraol-Glc 460 1.01
(a): Factors have been rounded to one signiﬁcant ﬁgure.
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Annex A – Additional calculations subchronic BMD
Annex A can be found in the online version of this output (‘Supporting information’ section): http://
onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.4655/abstract
Description: Additional calculations subchronic BMD – PDF ﬁle supplemented by Subchronic
calculation-PROAST excel ﬁle.
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